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SUMMARY
The an ti-a lle rgy  drug FPL 52757 (Tisons L td .,) 6 ,8 -d ie thy l-5 -  
hydroxy-^oxo-AH^-benzopyran^-carboxylic acid produced mild and reversible 
hepatotoxicity in some patients during c lin ica l t r ia ls .  The purpose of 
this work was to elucidate the mechanism by which FPL 52757 caused hepato- 
to x ic ity . However, since further humans could not be tested the work is 
lim ited to animal models. Toxicity studie s ; showed that the beagle dog was 
the only animal species of ten tested which was readily susceptible to the 
hepatotoxic'effect o f the compound. In this project hepatotoxicity could 
not be demonstrated in ferrets or rats in special studies designed to 
reduce resistance to drug-induced hepatotoxicity. S im ilarly , hepatic 
microsomal enzyme induction in dogs by pretreatment with phenobarbitone 
and protection against cytotoxicity by pretreatment with methionine provided 
no evidence for involvement of a reactive metabolite in the hepatoxicity.
Work by Fisons and additional studies in this project showed that 
the compound was extensively metabolised and rapidly eliminated by most 
species. Plasma clearance by the dog and man was in comparison slow,and 
due mainly to elimination of unchanged compound. As the dog and man are 
particu larly  susceptible to FPL 52757 induced hepatotoxicity the parent 
compound was implicated as the hepatotoxic agent. Species which cleared 
the compound rapidly compared with the dog did not readily show a hepato­
toxic response.
The tox ic ity  o f FPL 52757 tn retrograde b ilia ry  infusion studies 
in ra t and in the lysis of erythrocytes was studied and related to the 
detergent properties o f the drug. Other chromones were also examined and 
a detergency/toxicity/structure/activity relationship was established.
Pharmacokinetic studies in dog were carried out and showed that 
FPL 52757 resulted in increases in b ilia ry  excretion of alkaline phosphatase, 
gamma glutamyl-transpeptidase and 5 '-nucleotidase which parallelled the b ilia ry  
concentration of FPL 52757 and was accompanied by reduction in b ile  flow. The 
excretory mechanism of FPL 52757 in the b ilia ry  trac t was shown to be saturable 
and could result in high hepatocellular drug concentration and subsequent 
l iv e r  damage in the dog. By implication from this work- the mild hepatotoxic 
e ffec t in man was lik e ly  to have been caused by the slow clearance and 
consequent build up in the liv e r  and b ilia ry  trac t of unchanged FPL 52757, 
the to x ic ity  observed being mediated by the membrane damaging potential o f 
high concentrations of the compound. As a consequence of this work i t  could
confidently be predicted that lower concentrations would be perfectly  
safe in  man.
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CHAPTER ONE 
Introduction
DRUGS, POISONS AND TOXICITY
A drug, according to the W.H.O. is "any substance which, when 
taken into the liv in g  organism may modify one of its  functions".
Drugs, in i t ia l ly  o f herbal origin-have been taken by man from ancient 
time for medicinal (e .g . Cinchona), pleasurable (e .g . opium and cocaine) 
and even religious (e .g . mescaline) reasons. Alongside the beneficial
effects of medicines come the problems of intoxication, addiction, and 
side-effects .
The naive division o f xenobiotics into drugs and poisons is man 
made and does not take into account Ehlich's concept o f selective 
to x ic ity . This misunderstanding has been propagated despite an apparent 
grasp of the fundamentals o f toxicology from as early as the fourteenth 
century. Paracelsus (1493-1541) notes that, "All things are poison for 
there is  nothing without poisonous qu a lities . I t  is only the dose which 
makes a thing a poison".
Most modern drugs are selectively toxic compounds, exercising the ir  
therapeutic effects by the selective poisoning o f some infectious or 
invasive agent or by the selective inhib ition of some enzyme system, 
subcellular membrane or endogenous substrate. Their c lin ica l response 
is frequently dramatic; the sp ecific ity  of pharmacological action is  high, 
and because of the frequently close proximity of the therapeutically  
effective dose to toxic leve l, dosage is often c r i t ic a l . When considering 
treatment the risks must be weighed against the possible benefits to the 
patients. For drugs'with a high potential for generalised to x ic ity  the 
prognosis fo r the untreated patient should be poor.
The twentieth century heralds the beginning of the drug explosion, 
starting slowly [e.g. asparine (Dreser, 1899 ) ,  novocain (Einhorn, 1905) 
and Salvarsan (Ehlich and Bartheim, 1912] and quickening considerably 
a fte r 1935 with the discovery of prontosil for the treatment of systemic 
bacterial infections. An ever increasing l is t  of toxic or adverse effects  
has accompanied this pro liferation  of drugs. Commonly the adverse effects  
are minor, and lim ited to diarrhoea, nausea or vomiting and the benefits 
to the patient outweigh the discomfort experienced. However, numerous 
cases of serious toxic si de-effects have occurred over the decades.
More recently an increased awareness of diseases has accompanied drug 
development, but this has not eliminated the chance that unpredicted 
serious side-effects may occur.
Causes of Drug Toxicity
The following causes o f to x ic ity  lis ted  below are b rie fly  
elaborated in this introductory section:-
-  Inappropriate drug formulations
-  Drug formulation affecting absorption rates
-  Pre-existing pathological conditions affecting drug excretion 
rates
Pre-existing pathological conditions affecting drug metabolism
-  Drug interactions (general)
-  Drug interactions caused by induction or inh ib ition  of drug 
metabolizing enzymes
Hypersensitivity and iodiosyncratic reactions to drugs
The examples chosen (see Table 1 .l)to  illu s tra te  the causes of 
to x ic ity  show how one or more factors may combine or how a chain of 
events might escalate to result in a toxic e ffe c t. They are not intended 
as a comprehensive review, but are presented to form a general introduction 
to the possible types of mechanism involved in drug to x ic ity .
Inappropriate drug formulations
Early drug to x ic ity  resulted not only from the active components but 
also from impurities and inappropriate formulations. This was highlighted 
in 1937 in the U.S.A. when an e l ix i r  of sulphanilamide dissolved in d i­
ethylene glycol was marketed. The recommended dose contained su ffic ie n t  
diethylene glycol to cause death.
Changes in drug formulation affecting absorption rates
Digoxin is a classic example of a drug with therapeutic and toxic  
doses only marginally separated. Changes in the formulation o f a digoxin 
preparation have been shown to lead to major changes in plasma levels o f 
the drug with consequent toxic si de-effects.
Pre-existing pathological conditions affecting drug excretion rates
In patients on streptomycin therapy who are suffering from impaired 
kidney function, the corresponding slow drug clearance can result in  
severe damage to the eighth cranial nerve.
Pre-existing pathological conditions affecting drug metabolism
The effects o f any drug undergoing metabolism in the liv e r  w ill be 
affected by hepatic disease. Drug metabolism w ill be impaired and the 
risk of drug to x ic ity  is increased, e.g . severe haemorrhage can follow  
dicumerol therapy. An extreme example of this phenomenon occurs in 
patients with congenital deficiency o f glucose-6 -phosphate dehydrogenase. 
Haemolysis can follow treatment with phenacetin, primaquine and n itro ­
furantoin in these individuals.
Drug interactions
Interactions between drugs may cause unpredictable toxic side effects  
and may take place simultaneously a t a number of s ites . For example, the 
anti-inflammatory agent phenylbutazone competes with the anticoagulant 
warfarin for plasma binding, metabolic deactivation and renal tubular 
excretion. The overall effects are a reduction of the plasma level o f 
warfarin and its  more rapid clearance from the body, yet because more of 
the drug is available at the receptor sites in the liv e r  the anticoagulant 
a c tiv ity  is increased (O 'Reilly and Levy, 1970).
Drug interactions caused by induction and inhibition of drug metabolising 
enzymes
The toxic consequences of inducing hepatic drug-metabolising enzymes 
can be illu s tra te d  by the interactions of phenobarbitone and bis-hydroxy- 
coumarin. The anticoagulant is more rapidly metabolised when administered 
with phenobarbitone and withdrawal of phenobarbitone w ill eventually lead 
to restoration of drug metabolising enzymes to th e ir normal leve ls . The 
corresponding reduction in the metabolic deactivation of the anticoagulant 
may resu lt in spontaneous haemorrhage i f  the dose of bis-hydroxycoumarin 
is not simultaneously reduced (Cuci.nel],,et al_, 1965). Metabolic 
inh ib ition  by monoamine oxidase in h ib ito r w ill result in decreased 
metabolism of a number of drugs, e.g . pethidine which can lead to 
intoxication (Clark and Thompson, 1972).
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Hypersensitivity and idiosyncratic to x ic ity
These reactions occur in a small number o f patients. This type of 
response occurs with p e n ic illin . The mammalian to x ic ity  is so low that 
i t  can be regarded as the most innocuous o f a ll an ti-bacteria l drugs. 
However,.a small proportion of patients become sensitized to i t .  These 
two unpredictable classes include severe and dangerous toxic effects  
such as liv e r  necrosis, cholestatic jaundice, blood dyscrasias and 
anaphylactic shock.
"The extent and rate o f absorption, d istribu tion , metabolism and 
excretion of a drug may a ffec t not only the pharmacological response to 
the drug but also its  potential toxic ity" (Parke, 1972). From the l is t  
of causes of drug to x ic ity  a ll but the f i r s t  and las t had in common a 
pharmacokinetic basis of to x ic ity , illu s tra tin g  the importance of this 
phenomenon in drug to x ic ity . The subject o f toxico-kinetics and mechanisms 
of to x ic ity  are further explored la te r  in this introductory chapter in 
the section on metabolism and species variation in pharmacokinetics.
Safety Evaluation of Drugs in Animals
Dreser in  1899 evaluated the to x ic ity  of acetyl s a lic y lic  acid on "one 
small fish and two freshly captured frogs'. Animal to x ic ity  testing has 
become increasingly sophisticated; however, the aims are s t i l l  the same, 
namely, to reduce the risk o f adverse drug-effects in man. The testing  
of potential drugs in animal species is  now well established. Prior to 
marketing, a new drug must undergo successful c lin ica l t r ia ls  and before 
th is the metabolic and pharmacokinetic p ro file  o f a drug must be intensively  
explored in animals in both acute and chronic to x ic ity  tests. Administration 
of the drug to a small number of human volunteers a t this stage to elucidate 
the pharmacokinetic p ro file  in man can greatly improve the choice o f animal 
species for long term testing, thus increasing the chance o f finding toxic 
side-effects in animal species that may eventually occur in man.
No species exactly mimics man in the way i t  handles a ll chemical 
substances. Nevertheless, for every chemical there may be an animal species 
with sim ilar metabolism and excretion to man. In some instances past 
experience with a compound w ill enable reasoned choice of suitable species 
for testing a sim ilar drug. The use of a number of species including a t 
least one non-rodent type is ju s tif ie d , since a drug action that occurs
in a number of species probably involves a common physiological 
mechanism which is lik e ly  to be present in man. Conversely, a 
s ide-e ffect seen in only one o f a number of species might be thought 
to be an e ffec t peculiar to that species and less lik e ly  to occur in  
man, unless i t  is this species that man resembles more closely than 
any other.
Even when animal species handle a drug sim ilarly  to man, other 
major differences, such as re la tive  organ weight, l i f e  span and 
gestation period w ill provide d iff ic u lt ie s  in extrapolation of 
toxicological data from animals to man. Hence, in protecting the 
human population from drug to x ic ity , animal studies should be regarded 
as risk-reducing and not risk-elim inating. There s t i l l  remains the 
chance that unpredicted side-effects may occur as with thalidomide 
(Curran, 1971), practolol (Wright, 1974), and clo fibrate (O liver,
1978). Nevertheless, with current comprehensive practices, predict­
a b ility  is high and in addition to protecting man from drastic toxic effects  
animal studies can give information on lesser undesirable effects which 
might occur during c lin ica l tr ia ls  and la te r  when a drug is used more 
widely.
Pharmacokinetics and the Consequences of Species Variation  
Drug metabolism
The important role o f metabolism in the determination o f the pharmaco­
kinetic  p ro file  of a drug has been alluded to in the preceding pages.
Apart from elimination from the body o f unchanged compounds, fo r example 
by the kidney, the pharmacological and therapeutic actions o f a drug are 
lim ited by the metabolism brought about mainly by enzymes o f the liv e r .
This metabolic deactivation is purely fortuitous, resulting from the action 
of enzymes whose function is presumably to protect against the accumulation 
and undesirable effects o f anutrients, naturally present in the food and 
in the environment (Parke, 1968). The behaviour is the same towards drugs 
as towards the natural xenobiotics and although leading ultim ately to the 
deactivation and excretion of the drugs, may a t f i r s t  resu lt in enhanced 
therapeutic a c tiv ity  (activation ), changed a c tiv ity  or increased to x ic ity  
(in tox ication ). In ter and intra-species variatipn in the pharmacokinetic 
response to drugs may be great. Within a given population there w ill be
a normal distribution in the pharmacokinetic p ro file  of a drug and in  
some individuals variation can be extreme. (This has already been 
illu s tra te d  by the example of defective phenacetin metabolism in 
individuals with defic ient glucose-6-phosphate dehydrogenase). The 
consequences o f inter-species variations in toxicology and th e ir under­
standing are a pre-requisite for sound drug safety evaluation.
Species variation in anutrient metabolism
Pharmacokinetic differences, that is ,  differences in absorption, 
distribu tion , metabolism and excretion w ill account for species variation  
in response to anutrients. However, the type of mechanism o f to x ic ity  
and how an animal species ‘ handles' a compound w ill d ictate the response 
of the individual species e ither promoting or lim iting the toxic 
potential o f a drug. Since the extent o f metabolism w ill be shown to 
play a key role in the to x ic ity  o.f the drug under investigation in this  
thesis, thfs section includes a lim ited outline on the metabolism and 
excretion of foreign compounds (fo r comprehensive reviews see, Parke 1968;
La Du e t aT, 1971; Goldstein e t £l^, 1974; Gerok e t a\_9 1975 and Parke,1980).
Drug metabolism undertaken mainly in the liv e r  is an enzymic process, 
usually involving two phases -
Phase I Biotransformations
Phase I I  Conjugations
Phase I reactions can be classified as oxidations, reductions and hydrolyses 
in which hydroxyl, carboxylic, amino and occasionally sulphydry! groups are 
introduced, which increase the po larity of the molecule and act as a centre 
for conjugation. Phase I I  conjugations occur when a foreign compound or 
a product of Phase I combines with naturally occurring molecules in the 
l iv e r , such as glucuronic acid, generally making the molecule more polar 
and more readily excreted. In most animal species anutrients may be 
metabolised by e ither one or both phases. Either way, metabolism usually 
leads to detoxification. Species variation in the amounts o f specific  
enzymes w ill a ffect both Phase I and Phase I I  metabolism. However, Phase 
I I  species variation is mainly dependent on the a v a ila b ility  o f conjugating 
agents, for example, taurine conjugation is  a minor process in  most species 
but is important fo r the fe rre t (James et; al_, 1972). Numerous examples 
of Phase I variation ex is t, e .g . amphetamine metabolism occurs in ra t but
not in guinea-pig (_wi^ 1 i ams> I 96? ), guinea-pig metabolism of 6-chloro-5- 
cyclotoxylindane-I-carboxylic acid is minimal in guinea-pig compared with 
mouse (Parke, 1980), and the dog is unable to hydroxylate the a lic y c lic  
and aliphatic  carbon atoms of compounds readily hydroxylated by a number 
of other species (Dayton e t a l,  1973; Gros e£ al_, 1974 and Zacchei e t a l ,
1978). Reviews in this f ie ld  document a great many examples o f this  
sort (Hucker, 1970; Kato, 1979; Parke and Williams, 1969; Walker, 1978; 
Williams, 1967 and Williams, 1974).
Within the cell the enzymes which catalyse these reactions may be 
found in the mitochondria, the cytosol, and particu larly  in the endoplasmic 
reticulum where the enzyme system responsible for oxidizing most anutrients 
the microsomal mixed-function oxidase (M.F.O.) system is membrane bound. 
Enzyme a c tiv ity , particu larly  of the M.F.O. system o f d iffe ren t species, 
may largely influence species differences in drug metabolism. Many 
investigators have studied the components of the M.F.O. system in a number 
of species, to correlate differences in component levels with metabolic 
differences. For example, Kato (1966) showed that an iline hydroxylase 
a c tiv ity  in d iffe ren t species corresponded with levels of cytochrome P-450 
and cytochrome c reductase a c tiv ity . Although his recent review (Kato,
1979) illu s tra tes  the d iff ic u lt ie s  other workers have found in  establishing  
a clear relationship between xenobiotic metabolism in d iffe ren t species and 
th e ir  hepatic content of cytochrome P-450 or other M.F.O. system components 
i t  is generally agreed that a relationship must exist between species 
differences in component levels of the M.F.O. system and the metabolic 
capability of each species and this relationship probably consists o f 
multiple variables and w ill be influenced by the a c tiv ity  of other 
detoxifying microsomal enzymes e.g . epoxide hydrase and glucuronyl 
transferase.
Metabolic capability ini vij/o will be affected by the b io ava ila b ility  
of a drug. Anatomical and physiological species differences w ill cause 
differences in absorption, distribution and excretion. Recent studies 
indicate the importance o f protein binding, hepatic blood flow and the 
volume o f distribution (Wilkinson and Shand, 1975) in hepatic bio­
a v a ila b ility  and clearance. Some other in flu en tia l features affecting  
b io ava ilab ility  in d ifferen t species are lis te d  and/or b r ie f ly  discussed 
below:-
( i )  Concentrating capacity o f the liv e r  and differences
in glutathione levels
( i i )  Presence or absence o f a gall bladder
( i i i )  Bile flow rate
(iv ) Threshold molecular weight for b ilia ry  excretion
(v) ' Relative organ s iz e . ' Large vertebrates tend to have
re la tiv e ly  small livers (Munro, 1969), which leads 
into the observation that large mammals show low 
re la tive  mono-oxygenase ac tiv ity  when measured in  
terms of body weight (Walker, 1978).
Species variation in k inetic aspects of metabolism
Walker correlates metabolic rate and body size for a number of 
compounds metabolised by the M.F.O. system. I t  was Brodie who f i r s t  
presented the concept that species differences in the pharmacological 
response to a drug correlate with its  rate of metabolism and its  plasma 
level (Quinn e t al_, 1958; Brodie, 1964; Brodie and Reid, 1967). Marked 
species differences in the h a lf - l i fe  of hexobarbital metabolism among 
mouse, rabbit, ra t , dog and man were observed. A relationship between 
duration of drug action and biological h a lf - l i fe  was established, as 
well as inverse relationship between enzyme a c tiv ity  and duration of 
response (see Table 1 .2 .overleaf).
In this work Walker's hypothesis on body size and metabolic rate  
holds well with the exception o f rabbits. However, his 's ize -ra te  
relationship' does not hold fo r xenobiotics where additional factors or 
metabolic routes other than the mono-oxygenase system are equally 
important. I t  does not generally apply to conjugation reactions or to 
non-cytochrome P-450 oxidative reactions. Hence, there w ill be numerous 
occasions where this relationship does not hold, as with isoxepac ( I l l in g  
and Fromson, 1978) and the oxidatively metabolised compound phenylbutazone 
(Burns e t 1965). I t  is evident that i f  any compound is given to more 
than one species, then a species difference in the amounts and rates of 
metabolism are lik e ly , often with differences in the route of metabolism. 
Although, these differences are largely unpredictable, once a difference 
is found with a compound i t  is lik e ly  that related substances w ill behave 
sim ilarly  and exhib it sim ilar patterns of species varia tion .
Table 1.2 Species differences in the duration of action and
in the metabolism of hexobarbital
Species Duration o f action (min)
Biological
h a lf - l i fe
(min)
Relative enzyme
a c tiv ity
(mg/g/hr)
Mouse 12 19 598
Rabbi t 49 60 196
Rat 90 140 134
Dog 315 260 36
Man
"
360
'
Data from Quinn e t al_ (1958)
Toxicokinetic aspects of species variation in metabolism (and the mechanisms 
involved in reactive metabolite to x ic ity ).
Although metabolism generally results in detoxification, i t  is  now 
realised that the same metabolic systems can produce reactive intermediates 
in the form o f epoxides, hydroxylamines, free radicals or carbenes, with 
the possib ility  of a toxic manifestation. The variations in response to 
hepatotoxins w ill be in tr in s ic a lly  linked to the metabolic capabilities  
of d ifferen t species. For instance, i f  a compound (A) exerts a hepato­
toxic e ffec t via a reaction metabolite (B), metabolism to th is intermediate 
w ill be a pre-requisite for to x ic ity .
(A) Ki (B) K2 (C) 
 >
A = parent compound 
B = reactive metabolite 
C = non-toxic end metabolite
Figure 1. A sim plified metabolite pathway
Species which convert A to B rapidly ( i . e .  Ki, reaction rate is high) 
resulting in sustained high plasma and tissue levels o f B w ill be 
susceptible particu larly  those in which the enzymic conversion from B
to C is slow ( i .e .  K2 reaction rate is low). The mouse illu s tra tes  
this toxicokinetic principle since i t  possesses high mono-oxygenase 
a c tiv ity  (Ki ) but low epoxide hydrase (K2 ) and as a result is 
comparatively susceptible to toxic effects mediated by epoxides (Oesch 
e t aj_, 1977). In less susceptible species Ki may be comparatively low 
and K2 o f an equivalent rate . Numerous examples of compounds requiring 
metabolic activation ex ist; probably amongst the most well documented is  
paracetamol (Davies e t a l , 1974; Jo llow et cf[, 1974; Potter e ta l_ , 1974 
and G ille tte , 1977) currently thbught to produce to x ic ity  via an imidoquinone 
(G ille tte ■ e t'a l>,’l 980) I f  the parent compound (A) is toxic species suscept­
ib i l i t y  w ill be reversed. In this situation those species capable of 
metabolising the parent compound rapidly w ill be protected. Species 
unable to detoxify the compound w ill be at greater r is k . Thus metabolic 
capability and metabolic rate play a major toxicokinetic ro le , often 
determining whether toxic levels of anutrients or th e ir metabolites are 
achieved in  an animal species. The consequences of microsomal metabolism 
have been summarised by Parke, 1980, as follows:-
1. Detoxification and accelerated excretion o f metabolites.
2. Activation and reaction with ce llu la r components, e lic it in g  
toxic reactions.
3. Ligand complex binding to cytochrome P-450 with inh ib ition  or 
destruction of th is enzyme, resulting in autoxidation and non­
specific oxidation of environmental chemical substrates.
Reactive metabolites in to x ic ity  are well documented (Parke, 1980). 
Selected mechanisms w ill be described here because of th e ir  relevance 
to this thesis. These are best illu s tra ted  by specific examples (see 
Figure 2 ).
Hepatotoxicity mediated by reactive metabolites is produced through 
attack on v ita l hepatic macromolecules by e ither one electron (rad ical) 
or two electron (Cations,invidoquinones epoxides) e lectrophilic  reactions. 
These reactive intermediates are potent oxidising agents (Calder et al_, 1975 
depleting tissue glutathione, oxidising and binding with other v ita l 
tissue components resulting in hepatocellular necrosis. Some reactive 
metabolites may exhibit spec ific ity  in th e ir  a f f in ity  for sub-cellu lar
C12C=CC12
/ 0 \  
C12C— CC12 CC13 C0C1
N-NO CH3 and
Figure 2
components, for example, diol epoxides form stabilized internal ion-pair 
compounds that react as carbonium ions with DNA even in the presence of
epoxide need exist for DNA arylation and consequent damage o f DNA and 
carcinogenesis (Hulbert, 1975). The more usual sequence of events in  
the development of to x ic ity  is envisaged as glutathione-reactive metabolite 
interaction resulting in depletion o f glutathione levels . Once this has 
occurred the reactive intermediate is free to bind with other subcellular 
components to produce tox ic ity  and necrosis.
Thus glutathione and additional microsomal enzyme systems (e .g . 
epoxide hydrase) can be viewed as secondary defence lines should the 
primary defence lines in the form of the M.F.O. system activate (rather 
than detoxify) a foreign compound.
Cytochrome P-450 is the target fo r another type o f specific binding 
of reactive metabolites or metabolic by-products. Safrole, for example, 
following hydroxylation, loses water molecules to form carbenes which 
ligand complex with cytochrome P-450. Many halogenated compounds such 
as carbon-tetrachloride, chloroform and halothane are thought to act in  
a sim ilar manner (Parke, 1979). Sulphur containing compounds can lose 
sulphur in exchange for oxygen following M.F.O. a c tiv ity . The sulphur 
so released can bind with cytochrome P-450, resulting in a lowering of 
M.F.O. a c tiv ity  and eventually in hepatocellular damage (Parke, 1980).
glutathione and proteins, so that no threshold concentration of diol
I t  is recognised that vu lnerab ility  of the liv e r  to toxins is a 
result o f its  s ite  in  the body. Situated between the in testina l trac t 
and the general circulation makes i t  the1target organ1 fo r foreign 
compounds. The liv e r  receives foreign compounds via the hepatic 
portal vein, on th e ir f i r s t  pass before they enter the systemic 
circu lation . Exposure of the liv e r  w ill be maintained a fte r  a substance 
is  in the general circulation by the hepatic artery or by the hepatic 
portal vein i f  enterohepatic circulation occurs. Hence toxic compounds 
may be concentrated in the liv e r  prior to metabolism and elimination or 
i f  hepatic bio transformations produce toxic metabolites primary exposure 
of this organ to the toxic insu lt w ill s t i l l  occur.
Species Dependent Toxicity o f FPL 52757
A chromone, 6 ,8-diethyl-5-hydroxy-4-oxo-4 Hr T-benzopyran-2 -carboxylic acid 
(FPL 52757) was developed as an effective an ti-a lle rgy  agent (Augstein, e t a l , 
1977). Animal to x ic ity  data was obtained in several species to support 
human volunteer tolerance and c lin ica l studies. No adverse effects were 
found in human volunteers treated for 14 days a t 300 mg day"^ (equivalent 
to 4.5 mg kg~^day~^) . Subsequently one month tr ia ls  were carried out in
asthmatic patients. No abnormalities were seen in patients treated at
-1 -1100 mg day but some who received 300 mg day (approximately 20% of
those treated) showed significant increases in serum alanine amino­
transferase (ALT) and serum aspartate aminotransferase (AST) indicative  
of an e ffe c t on the l iv e r . No other liv e r  function tests were abnormal 
and no other adverse effects were seen. These findings, although mild 
and readily reversible were su ffic ien t to in h ib it the further development 
of the compound a t this dose for long term use in asthma. The animal data 
accumulated prior to c lin ica l tr ia ls  had fa iled  to predict this apparent 
sensitiv ity  of the human liv e r  to the compound. Consequently, additional 
studies in a variety o f species were undertaken and the species-dependent 
nature and mechanism of FPL 52727 to x ic ity  is elucidated in this thesis.
A summary of a ll the animal toxicology data follows the next section on 
chromones.
THE CHROMONES
) -
History o f chromones
FPL 52757 is a member o f the chromone group of drugs, of which 
disodium; cromoglycate# marketed as 'In ta l '  since the late  1960's, is  
the most well known. Altounyan (1967) and Pepys et al_ (1968) described 
the action of the bischromone derivative disodium- cromoglycate■ in  
preventing experimental asthma in man. Administration by inhalation  
effec tive ly  reduced the asthmatic response to inhaled antigen in 
sensitized individuals and this protective e ffec t lasted fo r several 
hours. No a c tiv ity  was found when the compound was given o ra lly . The 
chemical approach to this discovery was based on the long-known smooth- 
muscle relaxing effects of plant extracts containing K hellin , to which 
i t  is chemically related. However, the anti-asthmatic properties o f 
disodium (cromoglycate are not attributed to these effects which the 
drug does not possess, but to another action involving suppression of 
autacoid release. Since its  introduction in 1968 disodium; cromoglycate j 
has been widely used in Europe in the prophylaxis of severe bronchial 
asthma.
Pharmacological effects
D i s o d i u m  cromoglycatev inh ib its the release of histamine and slow- 
reacting substance (SRS-A) in anaphylaxis from human lung during a lle rg ic  
response. Both these substances, especially SRS-A, are potent bronchial 
spasmogens. An inhibitory action on antigen-induced production o f histamine 
and SRS-A has been demonstrated in peritoneal mast cells in vivo and in 
v itro  (Garland and Mongar, 1974). Disodium chromoglycate does not in h ib it  
fixation  of antibodies, nor does i t  seem to in terfere  with the anti gen- 
anti body reactions, rather i t  suppresses the response to th is reaction.
The need for the oral-acting chromone derivative
Despite the undoubted success o f disodium cromoglycate in asthma 
therapy and its  lack of toxic side-effects there is an even greater 
potential for an o ra lly -e ffec tiv e  anti-asthma drug. Disodium cromoglycate 
is poorly absorbed ora lly  and is only e ffective c lin ic a lly  when administered 
d irectly  to the target organ. D iffic u ltie s  arise from this route of 
administration, despite the development o f increasingly sophisticated 
and effective inhalers.
The problems encountered with this route include the following:-
(1) Patient compliance is variable; some patients find s e lf­
administration with the aerosols uncomfortable and d islike  
using them.
(2) Patients may misunderstand the instructions of th e ir physician.
(3) Other patients fu lly  understand these instructions and are w illing  
to comply with the therapeutic regime. Nevertheless, amongst this 
group misuse w ill s t i l l  occur, e.g . accidentally swallowing the 
drug instead of inhaling i t .
An o ra lly -e ffec tive  an ti-a llergy  compound should reduce the problem 
of patient compliance and enable the drug dose level to be better 
regulated.
FPL 52757 has been shown to be active by the oral route in  both 
experimental and c lin ica l asthma. Like disodium cromoglycate , FPL 52757 given 
by inhalation before antigen challenge affords protection. However, unlike 
disodium chromoglycate,FPL 52757 given in single or multiple oral doses of 
50-100mg from 2-12  hours before challenge,5 affords protection from anaphylactic 
broncho constriction. Both the immediate and the late reactions arising  
from antigen challenge appeared to be susceptible to treatment. In 
addition to these experimental results, further studies have shown that 
FPL 52757, given ora lly  (50 mg b .d .) over a period of one month, has 
afforded c lin ica l improvement.
ANIMAL TOXICOLOGY AND'SAFETY EVALUATION STUDIES ON FPL 52757 
Methods
Conventional toxicological techniques and study design (as outlined  
in ‘Guidelines for Preclinical and C linical Testing o f New Medical 
Products', Part I Preclinical by the Association of the British Pharma­
ceutical Industry, 1977) were followed including observation of behaviour, 
monitoring of body weight, food and water intake, comprehensive blood 
biochemistry and haematology screens, autopsy and microscopic examination 
of a range of tissues. Most of these studies generated negative data and 
are not described in d e ta il. The experiments carried out following c lin ica l 
tr ia ls  were designed specifica lly  for an evaluation of hepatotoxicity.
Dose levels for the longer repeated-dose studies were based on acute 
to x ic ity  data and on short duration (4 to 5 days) repeated-dose to x ic ity  
studies. Some studies were conducted by contract research laboratories 
as indicated in Table 3.
Results
Animal to x ic ity  stucjies prior to c lin ica l tria .ls .
Median lethal dose.
The intravenous single LD^ o f FPL 52757 following 14 days 
observation was approximately 100 mg kg~^  in rats and mice. The single 
oral dose LD^q (mg.. kg~^) following 14 days observation in  various species 
was as follows -  mouse 1800-1900; hamster 500-1000; ra t 700-900; 
rabbit 250-500 and cat 100-300.
Multi dose studies
A summary o f the repeated-dose studies with major and relevant 
findings are presented in Table T.3,and further details are given in 
Table 1, Appendix 1. Reproductive studies are included and although 
these were not designed as conventional tox ic ity  studies they provide 
additional evidence for the lack of hepatotoxicity and in  many cases the 
livers were subsequently examined microscopically with negative findings.
None of the five  species -  ra t, hamster, rabbit, squirrel monkey 
and cynoraolgus monkey, which were studied for periods of five  days to 
six months, showed any defin ite  evidence o f hepatotoxicity even when 
lethal or near lethal dose levels were administered. In some studies 
an increase in l iv e r  weight was found. (Details of liv e r  weight changes 
are shown in Table 2, Appendix I ) .  There was no evidence o f treatment- 
related pathological change in these cases.
Repeated dose to x ic ity  studies carried out subsequent to c lin ica l t r ia ls
A fter the results o f the c lin ica l tr ia ls  became known, c lin ica l 
experiments were done to investigate further the hepatotoxic p o te n tia l, 
of FPL 52757. These additional experiments included studies in rodents 
and other species including the beagle dog.
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Studies in mouse, ra t and rabbit (see Table 1 .4 , and Appendix 1 (Table:
>/
3 ) fo r fu lle r  details)..
High doses of compound produced minimal liv e r  changes. In mice 
there was a possible minor increase in aniline hydroxylase and s ligh t 
changes in the glycogen pattern. In ra t, electron microscopy o f the 
l iv e r  revealed a s lig h t degree of pro liferation  of smooth endoplasmic 
reticulum. In rabbit there were no dicernable changes in the l iv e r .
Studies in the beagle dog (see Table 1.5 §nd Appendix 1 (Tables 4 and 5) 
fo r fu lle r  d e ta ils ). •
Contrasting with the other species studied, FPL 52757 was re la tive ly  
toxic in dogs and caused death a fte r as few as six oral doses of 20 mg k g ~ \
A number of sequential studies were done which involved a to tal o f 33 
beagle dogs. Eight were control dogs and 25 were dosed ora lly  with FPL 
52757 at various dose levels. Most:FPL 52757 treated animals showed 
evidence o f drug-related hepatotoxicity. The to x ic ity  was accompanied 
by gross abnormalities in liv e r  function, confirmed by histochemistry and 
histopathology. Eight o f the animals died. Others lost considerable body 
weight and were k ille d  for humane reasons. Table 1.5 lis ts  the experiments 
and summarizes the dosing regimen and findings.
Severe gastrointestinal symptoms were observed in the dog, in
addition to hepatotoxicity. In several there was biochemical evidence
of liv e r  damage occurring very early and i t  may be inferred that FPL
52757 has a primary hepatotoxic action in dogs, with a theshold dose
- 1 - 1(in  the range 20-40 mg kg day ) and a steep dose response with 100 mg 
kg”  ^ day"  ^ being invaribaly le th a l. In some dogs hepatotoxicity appeared 
a fte r about one week of treatment with subsequent rapid deterioration, and 
in these cases there may have been gradual accumulation of the drug in the 
l iv e r  which eventually exceeded the threshold for hepatotoxicity. The 
release of the liv e r-sp ec ific  mitochondrial glutamate dehydrogenase (GLDH) 
and the rapid increases in plasma ALT, and to a lesser extent AST, were 
consistent with hepatocellular necrosis. Histopathology showed hepato­
b ilia ry  in jury with centrilobular necrosis and distended b ile  ducts; 
histochemical analysis revealed substantial increases in alkaline phosphatase 
(ALP) despite only comparatively s ligh t increases in serum alkaline  
phosphatase. When dosing of seven dogs was discontinued (see Appendix 1 ,Table 
l iv e r  function serum levels returned to normal in six animals; but in the 
seventh animal ALP continued to rise a fte r  cessation o f treatment, u n til
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death, despite substantial fa lls  in ALT, AST and GLDH. This 
observation and the high levels of ALP in other severely affected 
dogs emphasizes the importance of hepatobiliary injury in the 
escalation of hepatotoxicity. The pathological changes were 
generally consistent with a chronic toxic e ffe c t. Of the seven 
species the dog is uniquely susceptible to a hepatotoxic e ffect of 
FPL 52757. A relationship between these findings and the mild 
hepatic changes seen in man with the compound is suggestive but 
unproven. ‘
THE ORIGINAL HYPOTHESIS FOR THE MECHANISM OF FPL 52757 INDUCED 
HEPATOTOXICITY
The original hypothesis for FPL 52757-induced hepatotoxicity 
was based around metabolism to reactive intermediates. I t  was assumed 
at the outset o f this investigation in to  the mechanism o f FPL 52757 
induced hepatotoxicity, that the drug was well metabolised in most 
species. Hence i t  was postulated that metabolism of the chromone was 
necessary. A hypothetical metabolic pathway is shown in Figure 3, 
which includes iden tified  metabolites and possible intermediates in 
parentheses. With the discovery of the 6 - ethinyl metabolite 
[FPL 58280} in man i t  was thought this might be the hepatotoxic agent. 
However, in  animal species the occurrence of FPL 58280 did not correspond 
to the incidence o f to x ic ity .
A quinone methide could arise from the secondary alcohol [FPL 57704) 
possibly non-enzymically but perhaps catalysed by liv e r  enzymes. This 
tautomer of the vinyl metabolite would equilibrate with FPL 58280 or 
react with ce llu la r macromolecules. A lternatively , an epoxide formed 
from FPL 58280 could act in a sim ilar fashion. Examples of this type 
of interaction for both quinone methides [Hanson et aj[, 1970 and Turner, 
1966) and epoxides [Je'rina e t a l , 1974) are fam ilia r.
In the following chapters studies designed to elucidate the 
mechanism of FPL 52757-induced hepatotoxicity are described. The 
order of the chapters is based on the natural progression of the 
research programme.
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As data accumulated areas of in terest developed and certain facets 
of the mechanism are elaborated.
THE REASONS FOR UNDERTAKING THIS STUDY OF HEPATOTOXICITY
Prior to c lin ica l tr ia ls  with FPL 52757, five species, including 
two simians, received repeated oral doses for a period from 5-180 days. 
The chromone did not produce hepatotoxicity in any of these species even 
a t the maximum tolerated doses. The s u ita b ility  of these species as 
experimental models fo r man had been previously established on metabolic 
grounds; a ll of the species readily hydroxylated the drug, as did man. 
The clinico-pathological findings in man, although re la tive ly  mild, 
were nevertheless surprising. Further studies in rodents and rabbits 
fa iled  to demonstrate hepatotoxicity. Thus, in a l l ,  seven species were 
looked at carefully for evidence of hepatotoxicity. The toxic potential 
of this compound was realised only in dog (showing l iv e r  disturbances at 
doses approximately four times higher than those used in man). The 
mechanism in man and dog is not necessarily the same.
Hence the study o f the mechanism of hepatotoxicity of the chromone 
was in itia te d  for the following reasons -
(a) An understanding of the mechanism of biochemical to x ic ity
might be helpful in the design of new and non-toxic drugs
(b) I t  seems probable that a new type of biochemical mechanism
o f to x ic ity  might be uncovered
Cc) Chemical hepatotoxicity occurred in man which was not
previously observed in animal to x ic ity  studiesvan understanding 
of this species variation is important'for future drug evaluation.
CHAPTER TWO
EXPERIMENTS DESIGNED TO ELUCIDATE THE 
ROLE OF A REACTIVE METABOLITE IN FPL 52757 
HEPATOTOXICITY.
SUMMARY
Further species treated with FPL 52757 in multidose to x ic ity  
studies include the guinea-pig, fe rre t and baboon. FPL 52757 fa iled  
to  produce more than mild (and in the most part inconsistent) liv e r  
disturbances at doses 10-20 times greater than those causing hepato­
toxic side effects in man. The beagle dog was the only animal species of 
tenexamined which was readily susceptible to the hepatotoxic effect 
of the compound. Liver disturbances could be induced in in i t ia l ly  normal 
dogs a t doses approximately 4 times higher than those used in man. 
Hepatotoxicity could not be demonstrated in ferrets or rats in special 
studies including pretreatment with 3-methylcholanthrene or phenobarbitone,
defic ient d ie t and neo-natal animals, designed to reduce resistance to drug- 
induced hepatotoxicity and elucidate the mechanism involved.
S im ilarly , hepatic microsomal enzyme induction in dogs by pretreatment 
with phenobarbitone and protection against cytotoxicity by pretreatment 
with methionine provided no evidence for involvement of a reactive metabolite 
in the hepatotoxicity induced by FPL 52757.
INTRODUCTION
Chapter one includes a summary of safety evaluation toxicology 
carried out by Fisons Pharmaceuticals on a potential anti-asthma 
compound, FPL 52757. Subsequent experiments (conducted by the author 
unless otherwise stated) are described in th is and the following 
chapters which consist of supplementary studies beyond the normal 
scope of an industria lly  based pharmaceutical/company, nevertheless 
deemed both of academic and practical importance, for the reasons 
outlined in the previous Discussion. The aims of the multi-dose 
to x ic ity  studies described in this chapter were threefold: f i r s t ly ,  
to investigate the uniqueness o f the animal hepatotoxicity by carrying 
out further multidose to x ic ity  tests in untried ' species; secondly, 
to find a new small animal species susceptible to FPL 52757 to use as 
a suitable model fo r investigational studies by manipulation of 
conventional conditions for to x ic ity  testing i f  necessary; and th ird ly , 
to elucidate the original hypothesis for the mechanism of chromone- 
induced hepatotoxicity. These experimental designs were based on 
previously proven methods for demonstrating the role of a reactive  
metabolite in drug induced hepatotoxicity, by affecting the severity 
of damage (M itchell, et al_, 1973; Angeli-Creaves and McLean, 1979, and 
Parke, 1979). Detoxification by metabolism is commonplace; however, 
where drugs or toxic chemicals are activated instead of being detoxicated 
by metabolism, enzyme induction w ill lead to increased to x ic ity  (Parke, 
1979). The a b ility  of hepatic microsomal enzymes to produce toxic  
metabolites is altered by age (Kato et a l , 1964) and nutritional status 
(McLean and Day, 1975). Hepatotoxicity mediated by reactive metabolites 
can be decreased by selective pretreatment (e.g. methionine) aimed at 
protecting the hepatocytes (McLean and Day, 1975).
MATERIALS AND METHODS 
FPL compounds
FPL 52757 (6 )8-diethy1~5-hydroxy-4-oxo-4H-1-benzopyran-2-carboxy.'Hc
acid) is a stable crysta lline solid with the following physical properties 
M. wt. = 262, melting point 219-221°C, pK 1.4 , soluble in organic solvents
a
v ir tu a lly  insoluble in water. I t  was synthesized by Fisons Limited, 
Pharmaceutical Division, Loughborough, U.K. (Cairns, et al_, 1974) as 
were the metabolic standards(FPL 57704) 8 -e th y l-5-hydroxy-6-(i~hydroxy- 
ethyl)-4-oxo-4H-l-benzopyran-2-carboxylic acid, the secondary alcohol, .
8 ethyl-5-hydroxy-6-(2-hydroxyethyl-4-oxo-4H-l-benzopyran-2-carboxylic acid 
the primary alcohol? and(FPL 58280) 6-e th in y l-8-ethyl-5-hydroxy-4-oxo-4H- 
1-benzopyran-2-carboxy1ic acid the ethinyl metabolite. The major 
metabolite FPL 57704 was prepared by addition of S^ethyl'resacetaphenone to 
dimethyl-acetylenedicarboxyl ate, cyclysation w ith ’ chloroSulphonic acid ’ 
was followed by reduction to the secondary alcohol with borohydride. The 
primary alcohol was formed by reacting 3-ethyl- 2 ,6-dihydroxyacetophenone 
with a lly l bromide and the resulting 6-allyloxy-3-ethyl-2-hydroxyaceto- 
phenone condensed with diethyl oxalate to give the chromone ester.
Claisen re-arrangement to the a lly ! chromone, oxidative cleavage of the 
a lly l double bond to the 6-formylmethyl derivative and reduction with 
sodium borohydride gave the chromone ester with the desired substituents 
Alkaline hydrolyses of the ester afforded the required primary alcohol.
The ethinyl metabolite was prepared by dehydration of the secondary alcohol 
with dimethyl suIphoxide.
Their structures and that of FPL 52757 were confirmed by standard 
physical chemical techniques ( i . r . ,  u .v ., n .m .r.) and elemental analysis 
(see Table 2 .T ).
Other chemicals: 3-methylcholanthrene, phenobarbitone, methionine, sodium
chloride, methyl cellulose (Sigma Chemical Co., St. Louis, Missouri, USA). 
Corn o il (J. Sainsbury Ltd, London, England).
Animals: These were obtained as follows:- guinea-pig 340-390 gm, males 
(Duncan-Hartley, Animal Virus Research In s titu te , P irbright, Surrey, 
England); fe rre t 1.0-2.0 kg, males (A.S.. Roe, Norfolk, England); baboon,
8 kg, 1 male, 1 female (Shamrock Farms L td ., Henfield, Sussex, England); 
neonatal rats (Sprague-Dawley, Charles River, Manston, Kent, U .K ., and 
Surrey University Colony); rats 125 gm, males (Sprague-Dawley, Charles 
River, Manston, Kent, U .K., Fison's Colony); beagle dog 14-16 kg, male 
(Fisons Colony).
Animal Husbandry and Treatment
Prior to the study, a ll  animals were c lin ic a lly  examined and any 
animal below the necessary quality was rejected. Animal room temperature 
was controlled a t 21°C + 2°C, with a 50% humidity and lighting controlled  
to give 12 hours lig h t and 12 hours darkness per 24 hours. Water was free ly  
available to a ll  animal species via automatic drinking systems. Appropriate 
housing, d ie t, dose levels, dosing and sampling techniques varied with 
species and are described in detail for each study.
(* The primary alcohol was not designated an FPL number)
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Assessment of to x ic ity
Conventional toxicology techniques and study design were followed 
with special emphasis on assessment of liv e r  in jury.
Observation: Animals were observed periodically during the day for
changes in conditions and behaviour. Any animals showing signs of acute 
intoxication were k ille d .
Body weight:- Body weights were recorded on a regular basis. The 
regularity varied with species and intended duration of the study.
Food and water consumption:. Food and water intake was estimated on a 
daily  basis where possible.
Necropsy: A ll major organs from a ll  animals which died or were k illed
were examined fo r gross pathology. Routine weighing of livers was under­
taken. Histopathological examination included several sections from each 
liv e r  and other major organs. Sections were stained with haemotoxylin 
and eosin (H and E).
C linical chemistry: Appropriate tests designed to pick up adverse effects
on the liv e r  were carried out where possible at regular in tervals. The 
following enzymes are known to be markers for liv e r  damage: Isocitra te  
dehydrogenase (ICDH), alanine aminotransferase (ALT); alkaline phosphatase (ALP) 
aspartate aminotransferase (AST) and glutamate dehydrogenase (GLBH). A 
combination of at least two enzymes were investigated in each test (see 
Table 2 .2 ).
Table 2.2 Enzyme Analyses to Assess Hepatotoxicity
Experiment No. Species Enzymes
1 Guinea-pig ICDH, ALT, and ALP
2 Ferret ICDH, ALT, and ALP
3 Baboon GLDH, ALT, AST and ALP
4 Neonatal ra t
5 Rat
6 Ferret
7 Dog
ICDH, ALT and ALP 
GLDH and ALT 
ICDH, ALT and ALP 
GLDH, ALT, AST, and ALP
Plasma enzyme analysis is established as a sensitive means of 
predicting the progression of hepatotoxicity. To this end regular blood 
samples were taken throughout the fe rre t , baboon and dog experiments.
Only terminal bleeds were possible in certain species (e.g. guinea-pig 
and neonatal ra t) whose physiology and anatomy prevented regular sampling 
without considerable trauma to the animals.
The experiments were conducted by the author at the following locations: 
Experiment 1, 2, 4 and 6 a t the Animal Unit, University of Surrey, Guildford, 
Surrey, and Experiments 5 and 7 at the Hi 11 crest Research Station, Fisons 
Ltd ., Loughborough, Leicestershire. Experiment 3, the baboon study, was 
contracted to Hazelton Laboratories, Harrogate, West Yorkshire, under the 
direction of the author.
C lin ical Chemistry Methods
Measurements were carried out at the University of Surrey using the 
manual procedures outlined by Bernt and Bergmeyer (1974); a t Hazelton 
Laboratories, Boehringer Test Kits were employed, and at Fisons, analyses 
were achieved using established automated methods using a Vitatron AKES 
Enzyme Analyser. Fundamentally,the techniques and optimised standard 
methods are based on the following princip les:- ( i )  AST converts L-aspartate 
and a-oxoglutarate into glutamate and oxaloacetate. In an indicator reaction 
with MDH, oxaloacetate and NADH are converted into malate and NAD. AST 
ac tiv ity  is measured by the rate of decrease in absorbance o f NADH a t 
340 nm (Karman et al_, 1955) - ( i i )  ALT converts L-alanine and a-oxoglutarate 
into glutamate and pyruvate. In an indicator reaction with LDH, pyruvate 
and NADH are converted into lactate and NAD. ALT a c tiv ity  is measured by 
the rate of decrease in absorbance of NADH at 340 nm (Wroblewski and La Du, 
1956). ( i i i )  Alkaline phosphatase hydrolyses p-nitrophenol phosphate to 
phosphate and the p-nitrophenol liberated is proportional to ALP 
a c tiv ity , which is measured by the rate of increase in absorbance of p- 
nitrophenol at 405 nm (Hausaman£t al,1967(iv) GLDH, with the addition of 
ammonia and NADH, catalyses the ami nation of 2 -oxoglutarate, producing 
L-glutamate and NAD. * .The decrease in"-NADH concentration per minute 
(measured at 340 nm) is d irec tly  proportional to GLDH a c tiv ity  (Wallnofer 
e t .a l ,  1974). (y) Isocitra te is oxidised by ICDH using NADP as
coenzyme. The amount of isocitra te  oxidised is determined by the increase 
in extinction due to the formation of NADPH, which in turn is a measure of 
'ICDH ac tiv ity  (Bernt and Bergmeyer, 1974).
Quantitative Analysis of FPL Compounds
Levels of FPL 52757 and known metabolites were assessed from 
s e ria lly  obtained samples where possible and at autopsy from b ile , 
plasma, urine and faecal homogenates, using the following technique:
Known volumes. (0 .2: 2 ml ) were taken into
stoppered tubes arid acid ified  with an equal volume of 2N hydrochloric 
acid. Ten times the volume of hexane/ether (1:1 v/v ) was added and 
the tubes were shaken fo r ten minutes. The hexane/ether layer was 
removed, fresh hexane/ether wasadded and the extraction was repeated.
The combined hexane/ether layers were blown to dryness in a stream of a ir .  
The extracts were then redissolved in a known volume of ethyl acetate 
(50-lOOyl} and known volumes (5 -20yl) were spotted on to Merck glass- 
backed s ilic a  gel T.L.C. plates. The TLC plates were then developed in 
chloroform, diethyl ether, glacial acetic acid (6:2:2 v/v ) .  The TLC 
plates were then examined under UV lig h t before scanning on a Vitatron  
TLD using the transmittance mode and a 348 nm f i l t e r . .  - For comparison, 
standards of FPL 52757 and the common metabolites FPL 57704 and FPL
58280 were run through the procedure and used to estimate the levels
of compound present.
Part 1, Further studies in previously untested species.
The oral to x ic ity  of FPL 52757 in guinea-pig, fe rre t and baboon was 
exami ned.
Guinea-pig experiment: Groups of three male guinea-pigs were treated
orally  for up to 19 days with vehicle or FPL 52757 at 100, 200 and 300ng 
-1 -1kg day . FPL 52757 was suspended in vehicle (1% methyl cellu lose).
A ll animals were dosed at 10 ml kg  ^ via a ball-headed dosing needle
inserted through the mouth into the stomach. The guinea-pigs were allowed 
free access to p e lle t d iet (B.P. Nutrition (U.K.) L td ., Witham, Essex.
The guinea-pigs were housed 3 to a cage. Blood samples were taken by cardi 
puncture prior to euthanation, to assess drug-induced hepatotoxicity.
Ferret experiment: Three male ferrets  were treated for up to fiv e  days
either with vehicle or FPL 52757 at 200 or 400 mg kg day FPL 52757
was administered orally  as an aqueous suspension in 1% methyl cellulose
via a ball-headed dosing needle through the mouth into the stomach.
-1In i t ia l ly  animals were dosed at 5 ml kg ; this was reduced to 2.5 ml
-1kg on day 2 , and f in a lly  the ferrets were dosed twice daily with half 
the daily  dose of 2.5 ml~H9“  ^ to reduce the adverse effects of dosing.
The ferrets  were allowed free access to pelleted d iet (B.P. Nutrition (U.K.) 
L td ., Witham, Essex) mixed with cat food and housed one to a cage. Blood 
samples were taken by cardiac puncture prior to euthanation. A novel 
method for ta il-b leeding ferrets  (Bleakley, 1980) enabled serial samples 
to be collected for assessment of to x ic ity .
Baboon experiment: Two baboons, one male and one female were treated
for 28 days with FPL 52757 at 40 mg kg"  ^ day"  ^ (Days 1-7) 80 mg kg~  ^ day"^
- 1 - 1(Days 8-14, 16-28) and 160 mg kg day inadvertently given on day 15.
No control animals were included since pretreatment data was used as 
control values. Doses were prepared at the required concentration each 
day as suspensions in 1% methyl cellulose and were administered at a 
volume of 2 ml kg  ^ via a rubber catheter inserted through the mouth 
into the stomach. The monkeys were offered a Bonio biscuit (Spratts, 
Barking) weighing approximately 25g in the morning (a fte r  dosing) and 
approximately lOOg of Old World Monkey expanded primate d ie t (B.P. Nutrition  
(U.K.) L td ., Witham, Essex) and a fresh f r u i t  supplement in the afternoon.
A vitamin B-^ compound (Cytacon, Glaxo Laboratories L td ., Greenford, 
Middlesex, England) was added to the drinking water once a week. The 
monkeys were housed individually. Blood was withdrawn from the femoral 
vein, serial samples were regularly analysed to assess drug-induced 
to x ic ity .
Part 2. Investigational studies in species other than dog.
The potential of the chromone to cause hepatotoxicity in ra t and 
fe rre t was further investigated.
Neo-natal rat experiment: Groups of ten male, five-day old rats were
treated ora lly  with vehicle or with FPL 52757 at 100 mg kg ^day“  ^ suspended
-1in vehicle (1% methyl cellulose) dosed at 10 ml kg (via a ball-headed 
dosing needle inserted through the mouth to the stomach) fo r four days.
The rats were housed ten to a cage and allowed free access to a lactating  
mother. Blood samples were collected following decapitation, for 
assessment of to x ic ity .
Experiment to demonstrate the e ffect of deficient d iet and phenobarbitone
pretreatmentonTPL 52757 in the r a t : A d ie t deficient in selenium, vitamin
E and methionine (see Appendix 2) was provided by B.P. Nutrition (U .K .)
L td ., Witham, Essex. Groups of rats were divided as follows: Sub-group
1; four male rats received defic ient d ie t and vehicle o ra lly . Sub-group
2; four male rats received normal rodent d ie t (B.P. Nutrition L td ., Witham,
- 1 - 1Essex) and FPL 52757 at 200 mg kg day ora lly . Sub-group 3; sixteen
-1 -1male rats received the defic ient d ie t and FPL 52757 at 200 mg kg day
o ra lly . Sub-group 4; eight male rats received the defic ient d ie t, FPL
- 1 - 1  - 1 52757 at 200 mg kg day and phenobarbitone (1 mg ml ) in th e ir drinking
water. Sub-group 5, eight male rats received deficient d ie t, phenobarbitone
(1 mg ml"^) in th e ir drinking water and oral treatment with FPL 52757 at 
-1 -1400 mg kg day . The defic ient d ie t and phenobarbitone were given for
ten days prior to FPL 52757 or vehicle (1% methyl cellulose) dosed a t 10 ml
kg~^  via a ball-headed needle through the mouth into the stomach. The 
combined treatment was then maintained for 14 days. Serial blood samples 
were taken via the caudal vein fo r assessment of to x ic ity .
Experiment to demonstrate the e ffect of phenobarbitone and 3-methylcholanthrene
pretreatment on FPL 52757 in the fe rre t: Two groups of three male ferrets
were treated for up to 28 days ora lly  with FPL 52757 at 100 mg kg  ^ day ^
(suspended in 1% methyl cellulose) via a ' ba'll-headed needle through the
mouth into the stomach. One group was pretreated with phenobarbitone (40 mg
-1kg i .p .  fo r two days prior to and during the study) and the other with
3-methylcholanthrene (20 mg kg  ^ i .p .  fo r two days prior to and during the
study). The inducers were dissolved in sodium chloride and corn o il
respectively. Three control groups of 2 ferrets were treated for 28 days
-1ora lly  with vehicle alone or with phenobarbitone (40 mg kg i .p .  fo r two 
days prior to and during the study) and vehicle o ra lly , or with 3-methyl­
cholanthrene (20 mg kg  ^ i .p . for two days prior to and during the study) 
and vehicle ora lly . Phenobarbitone and 3-methylcholanthrene were administered 
i .p . at 1ml kg~^  and 2 ml kg~^  respectively. FPL 52757 was administered 
o ra lly  a t 1 ml kg \  The ferrets were allowed free access to a pelleted  
d iet (B.P. Nutrition (U.K.) L td ., Witham, Essex) mixed with cat food 
supplemented with a lOOg dead ra t (a fte r dosing). The animals were housed 
one per cage. Blood samples were taken either by cardiac puncture (terminal 
bleed only) or via the caudal vein, again making use of the recently 
developed technique for se ria lly  sampling in th is species (Bleakley, 1980) 
which enabled the severity of any drug-induced to x ic ity  to be assessed 
throughout the posing period.
Part 3. Investigational studies in the dog.
Effects of phenobarbitone and methionine on the to x ic ity  of FPL 52757 
to dogs.
Four male beagle dogs were treated ora lly  with the chromone in 1%
aqueous methyl cellulose (v ia  a rubber catheter inserted through the mouth
into the stomach, in a volume o f 0.5 ml kg”  ^ flushed through with 6 ml water)
in i t ia l ly  a t 30 mg kg”  ^ day~  ^ rising to 40 a fte r ten days in the absence
of hepatotoxicity. Two dogs received additional pretreatment. One received
phenobarbitone [20  mg kg"  ^ day”  ^ o ra lly  in water, 18 days prior to , and
30 days during treatment with FPL 52757. Another dog received methionine 
- 1 - 1at 300 mg kg day ora lly  in water 7 days prior to , and 42 days during 
treatment with FPL 52757. Induction was established in the phenobarbitone 
pretreated dog by measurement o f the antipyrine h a lf - l i fe  (t^?)* The two 
control dogs received FPL 52757 only. The dogs were offered 400g o f standard 
pelleted dog food (B.P. Nutrition (U.K.) L td ., Witham, Essex) a fte r  dosing. 
The dogs were housed ind ividually . Blood was withdrawn from the femoral 
vein and seria l samples were regularly analysed to assess to x ic ity .
RESULTS
The results section summarises the experimental detail relating to hepato­
to x ic ity . Tabulated Results are provided in Appendix 2.
Part 1. Studies on previously untested species (see Table 2 .3 ) .
Findings related to the liv e r .
Guinea-pig experiment: Following treatment of guinea-pigs for 19 days at
100 mg kg” day" ICDH levels were s ign ifican tly  raised (83%.p < 0 .1 ) , but
ALT and ALP were only s lig h tly  elevated. Small isolated areas o f s ligh t
necrosis with vacuolation in the necrotic areas were accompanied by
localized inflammatory responses in two 100 mg kg~^  day"  ^ animals (see
Figure i ) .  The liv e r  o f the th ird  guinea-pig was normal. In the higher
-1 -1dose groups (200 and 300 mg kg day ) FPL 52757 was highly toxic and the 
animals died or were k illed  before any significant hepatotoxic effects  
were manifested, although vacuolation of the liv e r  cytoplasm was seen.
Liver weight did not d iffe r  s ign ifican tly  between the control and the 
100 mg kg" 1 group.
*(The t |  for antipyrine was reduced from 
3.6 to 2.3 hr)
Ferret experiment: Following treatment of ferrets  for up to fiv e  days
either with vehicle or FPL 52757 at 200 or 400 mg kg day no adverse 
effects on the livers were detected even though the highest dose was 
le th a l. Liver weight, plasma enzyme and microscopic analysis a ll  
revealed no abnormalities.
Baboon experiment: Treatment of baboons with FPL 52757 (up to 160 mg 
for twenty-eight days raised levels of GLDH, AST, ALT and ALP 
up to 2 x normal levels. S light centrilobular necrosis, particu larly  
in the liv e r  from the male was .accompanied'by some b ile  duct erosion 
in both. j '._ • .
Part 2 Investigational studies in species other than dog (see Table 2.4) 
Findings related to the liv e r .
Neo-natal ra t experiment: Treatment of neo-natal rats fo r four days with
Tj ..1
FPL 52757 100 mg kg day or vehicle produced no differences in 
ALP, ALT and ICDH levels between the survivors in the test and 
control groups. Macroscopic and microscopic examination of liv e r  sections 
(including those from neo-nates which died during the study) revealed no 
abnormalities.
Experiment to demonstrate the effect of deficient diet and phenobarbitone 
pretreatment of FPL 52757 in the r a t : Dosing of rats (on deficient d iet
and those on a combination of phenobarbitone in th e ir drinking water and 
a defic ient d ie t) with FPL 52757 at 200 and 400 mg kg"1 was maintained for 
14 days. Some m ortalities occurred amongst rats which received the 
experimental d iet and FPL 52757 particu larly  in the high dose group where 
six out of eight died. Analysis of plasma transaminase, GLDH and micro­
scopic examination of livers fa iled  to indicate any adverse effects on the 
liv e r  even in moribund animals. (A possible slight increase in liv e r  
weight occurred in rats receiving experimental d iet and FPL 52757 compared 
with those receiving experimental d iet alone. A larger increase (x 2) in 
l iv e r  weight resulted from phenobarbitone and FPL 52757 treatment of rats  
on the deficient d ie t) .
Experiment to demonstrate the effect of phenobarbitone and 3-methylcholanthren 
pretreatment of FPL 52757 in the fe r r e t : Following treatment of fe rrets
receiving either phenobarbitone or 3-methylcholanthrene pretreatment with 
FPL 52757 100 mg kg~! day*^ plasma enzyme levels (ALP, ALT, ICDH) were 
elevated particularly  ICDH (up to 6 x normal levels ). Macroscopic and 
microscopic examination of the livers showed no general abnormalities
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except in one fe rre t which showed marked reversible toxic changes in 
centrilobular hepatocytes. This particular fe rre t,
in the 3-methylcholanthrene pretreatment group became anorectic during 
th is study. This may have altered the sens itiv ity  of the animal to 
FPL 52757. Liver weights were apparently normal in the group 
receiving phenobarbitone pretreatment but there was a possible.slight 
increase amongst those receiving 3-methylcholanthrene.
Part 3 Investigational studies in the dog
Experiment to demonstrate the e ffect of phenobarbitone and methionine 
on FPL 52757 to x ic ity  in dog (see Table 2 .5 ) : The two dogs receiving 
FPL 52757 only were autopsied on day 13 and 14, a fte r substantial 
increases in th e ir plasma enzymesfe.g. GLDH and ALT were increased 50 to 
200 fo ld ). Hepatotoxic damage was confirmed by microhistopathology; 
centrilobular necrosis was extensive with enlargement, pro liferation  and 
congestion of b ile  ducts accompanied by erosion of b ile  duct w a l l s  ( s e e  F ig .2.1 , 
2 .2 ,2 f3 and 2 .4 .The dog receiving FPL 52757 plus, phenobarbitone pretreatment 
survived fo r 30 days of drug treatment (see Table 2 .5 ). Despite two bouts 
of mild hepatic dysfunction, plasma enzymes were near normal when the dog 
was k ille d . Hepatotoxicity developed slowly in the dog receiving daily  
methionine (200 mg kg"^) pretreatment. However, severe FPL/52757-induced 
damage occurred twenty-seven days a fte r concomitant pretreatment with 
methionine was withheld. Trace amounts of metabolites were found in some 
plasma and b ile  samples from three of the dogs with no obvious correlation to 
pretreatment. High concentrations of the parent drug (5-8 mg ml”^) were 
found in gall bladder b ile  samples at post-mortem.
DISCUSSION
PART 1 .FURTHER STUDIES IN PREVIOUSLY UNTESTED SPECIES
This chapter describes toxicological assessment of the chromone in novel 
species, bringing the to tal number of species subjected to th is oral chromone 
treatment up to ten. v
Guinea-pig and fe rre t experiments: Studies in guinea-pig and fe rre t were
undertaken with expectations of identifying a new small and convenient 
animal species for investigative studies on the mechanism of hepatotoxicity  
of FPL 52757. Results in fe rre t and guinea-pig were'equivocal, although
-39-
Figure 2.1 Shows a section-iof l i v e r  from 
30 mg kg day i l lu s t r a te s  
(Magnification x 160, stained
a male beagle 
erosion of b i l  
w ith H & E).
dog receiving 
e duct wa lls .
f ig u re  2.2 Shows a section of normal dog l i v e r .
(Magnification x 160, stained w ith H & E).
1 >:•?. • ' • .
Figure 2.3 Shows a section o f l i v e r  from a male beagle dog receiving 
30 mg k g "1 day : C en tr i lobu la r necrosis is  evident with
enlargement p ro l i fe ra t io n  and congestion of b i le  ducts. 
(Magnification x 40, stained with H & E).
Figure 2.4 Shows a section of l: jver from a male beagle dog
receiving 30 mg kg"'day- ' .  C en tr i lobu la r necrosis 
is  evident. Necrosis occurs in a star-shaped pattern 
around the central vein.
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indications of disturbed liv e r  function occurred only a t nearly lethal 
doses. Hence, these species were deemed as probably being unsuitable 
animal models,for further investigations. Nevertheless, one further 
attempt to induce consistent reproducible hepatotoxicity in fe rre t was 
considered worthwhile, since this species could have great potential as 
a non-rodent species in special toxicological investigations and in routine 
safety evaluation toxicology.(This study is discussed la te r  in this section).
Baboon experiment: The baboon study was directed in case this species
showed a susceptib ility  sim ilar to man and greater than that o f the dog.
The baboon showed some disturbances of l iv e r  function at 80 mg kg~^  day”\  
This dose level may be compared with sim ilar changes occurring in man at
4-5 mg kg~^  day"^.
Only the dog, out of a ll  the animal species investigated, is re la tive ly  
sensitive to a hepatotoxic e ffec t of FPL 52757 showing l iv e r  disturbances 
at doses about 4 times higher than those used in man.
PART 2. INVESTIGATIONAL STUDIES IN SPECIES OTHER THAN THE DOG
A number of special studies are described in this chapter, based on 
previously proven methods for demonstrating the role of a reactive metabolite 
in hepatotoxicity (M itch e ll, e t a l , 1973; Angeli-Greaves and McLean, 1979 
and Parke, 1979) and reports that age affects to x ic ity  (Parke and Williams 
1969).
Neonatal ra t experiment: New born rats have low levels of microsomal
enzymes including cytochrome P-450. These enzymes begin to appear in the
f i r s t  few days a fte r  b irth  but do not reach maximum levels un til 30 days a fte r
birth (Kato e t 'a l ; 1964) The rationale for the f i r s t  study on neonatal
rats was based on the hypothesis that impaired metabolism in these immature
animals could lead to toxic manifestations, particu larly  as the LD^q in
neonatal rats is approximately 0.25 of that found in adult ra ts . There
were no signs of hepatotoxicity in neonatal rats a fte r 4 days of dosing
-1 -1with FPL 52757 at 100 mg kg day despite some m orta lities . I t  is 
evident that neither adult nor neonatal rats are susceptible to FPL 52757 
irrespective of th e ir  varying a b ility  to metabolise foreign compounds.
The resistance of neonatal rats could be viewed as suggestive evidence 
for the compound i ts e l f  being innocuous. However, subsequent experiments 
described in this chapter and la te r do not substantiate this view.
Experiment to demonstrate the effect of deficient diet and phenobarbitone 
pretreatment on FPL 52757 in the r a t : Low protein diets reduce liv e r  gluta­
thione levels(_Leef & Nauberger,1947). A d iet deficient in selenium, vitamin E 
and methionine has been shown to increase the susceptib ility  of rats to 
hepatotoxins. Phenobarbitone pretreatment makes the protein-depleted 
animals even more sensitive (McLean and Day, 1975). As FPL 52757 hepato- 
to x ic ity  was not produced in rats on a deficient d iet with phenobarbitone 
pretreatment, there was no evidence to support the existence of a toxic  
metabolite. The study emphasized the high degree of resistance of the rat 
to FPL 52757 induced hepatotoxicity. Even when lethal or near lethal doses 
were given to weakened animals with lowered resistance to hepatotoxins 
no pathological changes occurred in th e ir liv e rs .
Experiment to demonstrate the effect of phenobarbitone and 3 -methylcholanthrene 
pretreatment on FPL 52757 in the fe r re t : An additional attempt to produce 
consistent reproducible hepatotoxicity in fe rre t involved pretreatment with 
the two types of inducers, increasing the probability of FPL 52757 causing 
hepatotoxicity in this species, should a particular metabolic pathway be 
favoured. Phenobarbitone is regarded as a re la tiv e ly  non-specific inducer 
of microsomal enzymes, including cytochrome P-450 and increases the binding 
of Type I and Type I I  substrates whereas polycyclic hydrocarbons lik e  
3-methylcholanthrene replace cytochrome P-450 with cytochrome P-448 and 
promote Type I I  binding (Parke, 1975). Despite the toxic symptoms 
exhibited by some ferrets in the chromone treated groups, th is 28-day 
multi-dose study fa iled  to demonstrate the male fe rre t to be a useful model 
for FPL 52757 induced hepatotoxicity. Serum enzyme elevation indicated 
slight FPL 52757-induced hepatotoxicity in both the chromone-treated 
groups. Histological examination of liv e r  sections revealed no pathological 
changes in livers from the phenobarbitone treated group. However, in the 
3-methylcholanthrene group changes in blood biochemistry correlated with 
histological findings. Nevertheless, damage was not severe and was 
restricted to reversible toxic change. Anorexia in the most severely 
affected animal may have contributed to the manifestations of hepatotoxicity 
by producing hepatocellular changes which effective ly  sensitized the liv e r  
or influenced the pharmacokinetics of the chromone in this sick animal, 
allowing accumulation of the chromone in the liv e r . As no consistent 
hepatotoxicity occurred in the fe rre t , despite high doses of FPL 52757 
for 28 days in combination with metabolic inducers, no clear evidence for 
a reactive metabolite was provided.
Since species which metabolise and excrete the chromone rapidly 
(see Chapter 3) are not susceptible to the hepatotoxic e ffec t of the 
chromone and exhaustive attempts to implicate a reactive metabolite 
fa ile d , i t  may be implied that the parent compound is responsible for 
the hepatotoxicity. This conclusion must be viewed with caution when 
considering the rat and fe rre t investigational studies since neither of 
these species were susceptible to compound-induced hepatotoxicity.
However, a sim ilar study in the beagle dog, the animal species most 
susceptible to FPL 52757 induced hepatotoxicity provides further 
evidence for parent compound involvement,,
PART 3. INVESTIGATIONAL STUDIES IN THE DOG
Experiment to demonstrate the e ffec t o f phenobarbitone and methionine 
in FPL 52757 to x ic ity  in dog: Both phenobarbitone and methionine
decreased the hepatotoxicity of FPL 52757 in the dog. Methionine 
protects the liv e r  from hepatotoxicity by maintaining glutathione levels 
(McLean and Day, 1975), and the phenobarbitone-induced increase o f  
cytochrome P-450 usually results in an increased formation of a reactive 
metabolite (s'-) with an accompanying increase in hepatotoxicity. As the 
metabolism in dogs was nearly non-existent, despite induction of cytochrome 
P-450 with phenobarbitone, i t  is apparent that protection by both 
phenobarbitone and methionine must involve other e ffects . B ile flow 
rate is increased by both phenobarbitone (Maxwell, 1973) and methionine 
(Narodefskaya and Nasterin, 1974). The choleretic e ffec t of these 
compounds may have increased the chromone clearance rate and thereby 
protected the liv e r .
I t  has been observed on a number of d iffe ren t occasions that b ilia ry  
excretion of a compound can be increased by stimulating b ile  flow 
(Angelucci ejt _aT_, 1970; Klassen and Plaa, 1968; Klassen, 1970; Roberts 
and Plaa, 1967; Hart_et aT, 1969, and Goldstein and Taurog, 1968). The 
assumption for this possible method o f protection seems ju s tif ia b le  in 
the lig h t of the particu larly  high concentrations of FPL 52757 found at 
post-mortem in b ile  from the gall bladder of dogs receiving no pre­
treatment or where pretreatment had been withheld. Analysis o f b ile  
from the gall bladder of the dog receiving phenobarbitone pretreatment 
s t i l l  revealed a high b ilia ry  concentration of FPL 52757 (5 mg ml*" )^ but 
this level was approximately ha lf that o f the other dogs. Furthermore,
microscopic examination of the liv e r  revealed congested enlarged b ile  ducts 
with erosion of b ile  duct walls in severely affected dogs. The threshold 
molecular weight for b ilia ry  excretion varies between d ifferen t species 
(Hircm et 1972} and is dependent on the excretory process i ts e lf  and 
not differences in b ile  flow (Smith, 1973). However, where a b ilia ry  
excretory mechanism exists for a compound its  toxicokinetics may be altered  
by alterations in b ile  flow rate .
Species variation in the pharmacokinetics of FPL 52757 w ill be shown 
to be particu larly  important in . ( i )  explaining species variation in the 
incidence of to x ic ity  and ( i i ) adding further weight to*the development of an 
alternative hypothesis, fo r the mechanism of hepatotoxicity involving the 
parent compound. Species variations in the metabolism and kinetics of 
FPL 52757 are described in the following chapter.
CHAPTER THREE 
THE PHARMACOKINETICS OF FPL 52757
SUMMARY
The disposition of FPL 52757 in d ifferen t species has been 
investigated. The compound is extensively metabolised
by the following species:- mouse, ra t ,  hamster, rabb it, fe rre t, stump­
ta iled  macaque, squirrel monkey, cynomolgus monkey and baboon (e.g. 
50-100% in ra t , cynomolgus monkey and squirrel monkey). The plasma
clearance of FPL 52757 in ra t , rabbit and squirrel monkey was 138, 44 
- 1 - 1and 56 ml 'kg hr respectively. Plasma clearance by the dog and
-1 -1man was in comparison slow (13 and 15 ml kg hr respectively, and 
due mainly to elimination of unchanged compound in dog. In man 
minimal or partia l metabolism occurred (4-50%). As the dog and man 
are particu larly  susceptible to FPL 52757 induced hepatotoxicity the 
parent compound may be responsible. Species which clear the compound 
rapidly compared with dog and man did not readily show a hepatotoxic 
response. A sim ilar mechanism for dog and man is probable though not 
proven. In v itro  isolated rat liv e r  perfusion experiments are described. 
This technique enabled high concentrations of the chromone to reach the 
liv e r  without the complications of generalised FPL 52757-induced 
to x ic ity .
INTRODUCTION
In the preceding chapters the toxicology of FPL 52757 and the unlikely  
role o f a reactive metabolite in hepatotoxicity have been described.
This chapter outlines the metabolism and clearance of FPL 52757 and 
links the • two e a rlie r  chapters on a pharmacokinetic basis. Pharmaco­
kinetic analysis for a number of species, including man, was achieved 
by extrapolation from plasma concentration data accumulated during 
Fison's Safety Evaluation Programme. No such data existed for the dog., 
the one animal species readily susceptible to FPL 52757-induced hepato­
to x ic ity . Experiments are described in th is chapter which enable 
toxicokinetic comparisons to be made between the susceptible and 
resistant species on the basis of the length of exposure to the chromone. 
These investigations study the clearance of FPL 52757 in dog. The 
toxicological implications of metabolism and clearance of the chromone 
are considered.
I t  has been demonstrated that the ra t in vivo is highly resistant 
to FPL 52757 (see Chapter 2). The in v itro  isolated perfused ra t liv e r  
technique is employed to allow exposure of the liv e r to high levels of 
the drug without the problems of generalised to x ic ity . In i t ia l ly  
intended as a 'new animal model system' in which to study the role of 
reactive metabolites, the technique contributes toxicokinetic data.
As data accumulated implicating the parent compound in hepatotoxicity 
the isolated perfused ra t liv e r  programme was curtailed in favour of 
studies on the physico-chemical nature of chromones (see Chapter 4 ). 
Nevertheless, the limited data obtained from these few perfusion studies 
areincluded in this chapter. As only a small number of experiments were 
conducted the results must be viewed merely as further suggestive 
evidence of the importance of pharmacokinetics in FPL 52757“induced 
hepatotoxicity. More conclusive evidence comes with the in vivo 
results in this chapter and the more sophisticated toxicokinetic  
experiments in dog conducted at a la te r stage of this project (see 
Chapter 6 ).
MATERIALS AND METHODS
FPL compounds
FPL 52757 (micronised free ac id ), FPL 52758 (water soluble Na+
:sa lt o f FPL 52757), (14C) FPL 52757 (specific a c tiv ity  2.23yCi mg'1) ,
( C) FPL 52758 (specific a c tiv ity  3.10 yCi mg 1) were synthesized by 
Fison L td .,Pharmaceuticals Division, Loughborough, U .K., as were \  
the. metabolic/standards, . th e  secondary alcohol (FPL 57704) and 
the ethinyl compound (FPL 5.8280) (see Chapter 2 for further d e ta ils ).
Pharmacokinetic Studies
Animal species
Animals were obtained as follows - mouse, males and females, 40g 
(CFW, Fisons Colony), ra t , males and females, T25g (Sprague-Dawley,
Fisons Colony), hamster, males, lOOg (BioResearch Consultants, Boston,
Bio 15-16 inbred s tra in ), guinea-pig^ males, 350g (Duncan-Hartley,
Animal Virus Research In s titu te , P irbright, Surrey), fe rre t , males,
1 to 2kg; A.S. Roe, Norfolk), squirrel monkey, males and females,
0.5 to 0.9 kg, stumped-tailed macaque, males and females, 9kg, and 
cynomologus monkey, males and females, 2 to 4 kg (Fisons stock 
originated from the w ild ), baboon, male and female, 8 kg (Shamrock 
Farms Ltd, Herefield, Sussex), beagle dog, females 15 kg (Fisons stock).
Animal d iet
Water was free ly  available to a ll animal species via automatic 
drinking systems. Each species received a commercially available pe lle t 
diet (provided by B.P. N utrition, Stepfield, Witham, Essex) with 
appropriate supplements as follow s:-
Hamster, rats and mice - Oxoid Breeding Diet (Oxoid L td ., Basingstoke, 
Hants). Rabbits, Coney rabbit pellets No. 350 (B.O.C.M. Si lock Ltd, 
made up by T y rre ll, Byford and Pallet L td ., Station Road, Attleborough, 
Norfolk); ferrets , FDL pelleted d iet with a meat supplement (BP N utrition  
U.K. L td ., Witham, Essex); dogs Spratts No. 2 d ie t (Spratts L td ., Barking, 
Essex, England); monkeys, mixed d iet with fre s h -fru it and Newmarket cubes 
(Spillers-Spratts L td ., Barking, Essex); baboon, f r u i t  supplements, Bonio 
biscuits (Spratts, Barking, Essex, England); old world monkey expanded
primate d iet (B.P. Nutrition (U.K.) L td ., Witham, Essex), Vitamin B^  
(Cytacon, Glaxo Laboratories L td ., Greenford, Middlesex, England) was 
added to the drinking water.
Dosing of animals and man
A ll animals received oral doses of FPL 52757 by stomach tube or
via a ball-headed dosing needle in a suspension of 1% aqueous methyl
cellulose (M420 British Celanese). Human volunteers received oral
doses in rice paper cachets or gelatin capsules. Urine and faeces
were collected from animals in metabolism cages. Intravenous dosing
14was carried out using water soluble sodium sa lt ( C) FPL 52758 
(specific a c tiv ity  3.10 yCi mg"1) or { 14C) FPL 52757 (specific a c tiv ity  
2.23 yCi mg"1) dissolved in 2% sodium bicarbonate (Sigma Chemical Co.,
St. Louis, M.O., USA,).
14For clearance studies ( C) FPL 52758 was administered intravenously
at 10 mg kg 1 to the ra t, rabbit and squirrel monkey. The dog received
a range of doses (1-50 mg kg"1) 1Z^C FPL 52757. Human volunteers received
an intravenous dose of approximately 1 mg ml 1 of FPL 52758. Blood
samples were taken at regular intervals up to 72 hours a fte r administration
of the compound. Clearance, which is the volume of plasma cleared of
rad ioactiv ity  in one minute was calculated for animals from the area
14under the plasma ( C) concentration versus time curve,
i .e .  Plasma Clearance Dose
(where AUC is the area under the plasma concentration versus time 
curve extrapolated-to t= oo). in the case of man the plasma clearance 
of parent compound was determined. The values given for animals under­
estimate the actual clearances of parent compound depending on the degree 
of metabolism
Analysis of FPL 52757 and metabolites
Total urinary and faecal excretion and plasma concentration of radio­
ac tiv ity  in species receiving (^ C ) FPL.52757 and FPL 52758 were determined from 
the concentrations of rad ioactiv ity  obtained by liquid s c in tilla tio n  
counting of aliquots of urine, faeces homogenates and plasma. Samples
were dissolved in s c in tilla tio n  flu id  (Shellsol A 2 vo ls ., Triton X100,
- i
1 v o l., plus 6g l i t r e  of 2,5 diphenyloxazole). Radioactivity determinations 
were carried out using a Packard Liquid S c in tilla tio n  Spectrometer.
Metabolic patterns and concentrations of the chromone in human- samples 
and other animal species receiving 'cold' FPL 52757 were determined 
with extracts of urine, plasma and faecal homogenates using standard 
t . l . c .  techniques (see Chapter 2 ). Autoradiographs were prepared by 
placing t . l . c .  plates in contact with an x-ray film  (Blue, Brand Kodak 
L td .,)  in a lig h t-t ig h t cassette for fiv e  days, developing (Ilfo rd  PQ 
Universal Developer) and fix ing  (Kodafix, Kodak L td .).
Isolated Perfused Rat Liver Studies
Perfusion media.
A medium comprising 100 ml tissue culture medium 199 without phenol 
red (Difco Laboratories, D etro it, Michigan, USA), 2.5 bovine serum 
albumin, fraction v (Sigma Chemical Company, St. Louis, Missouri, USA),
500 units of heparin (BDH Chemicals L td ., Poole, Dorset) and 75 mg genta- 
mycin (Flow Laboratories L td ., Irv in e , Ayrshire) was prepared and 65 ml 
of th is medium made up to 100 ml with erythrocytes (washed with isotonic 
saline) to give the perfusion medium. The remaining ce ll free medium 
(35 ml) was used as the pre-perfusion medium.
Animals
Rats, 250g, male (Charles River, Manston, U.K.) were anaesthetized
-1with sodfum pentobarbitone (Nembutal, 60 mg kg ) and the b ile  duct and
hepatic portal vein of each cannulated with pp 25 and pp 60 polypropylene
tubing (Portex L td ., Hythe, Kent) respectively. An in situ infusion of
the liv e r with the pre-perfusion medium 10 ml min*^ was performed during
hepatectomy a fte r which the liv e r  was connected into a perfusion
system sim ilar to that described by Curtis et al (1970). In th is  system
the medium was oxygenated by a continuous stream of a moistened mixture
of 95% 09 and 5% C09 passing over a multibulb oxygenator. The liv e r  was
- 1 - 1perfused at a rate o f 1 ml min 9' liv e r  under a constant head of 30 cm 
perfusate ( i .e .  30 cm hydrostatic pressure) at 37°C. The perfusion 
medium containing substrate (FPL 52758) was allowed to equilibrate in the
system for 5 minutes before the introduction of the liv e r .
Table 3.1. Isolated Rat Liver Perfusion Experiments
Perfusion Number Treatment
PI Control, no addition of chromone.
P2 Control, no addition of chromone.
P3 100 mg of FPL 52758 was added to give a perfusate
-1
concentration of lOOOyg ml .
P4' 75 mg of FPL 52758 was added to give a perfusate
-1
concentration of 750 yg ml .
P5 40 mg of FPL 52758 was added to give a perfusate 
concentration of 400 yg ml ^.
P6 40 mg of FPL 52758 was added to give a perfusate 
concentration of 400yg m l~ \ The ra t liv e r  had 
prior exposure to SKF 525A 50 mg kg  ^ p.o. 
(Smith, Kline & French, Welwyn Garden C ity) one 
hour before hepatectomy.
Analyses and assessment of to x ic ity  from the perfusion experiments.
Perfusate samples were collected regularly for analyses of the serum 
enzymes isocitra te dehydrogenase (ICDH), alanine aminotransferase (ALT) 
and alkaline phosphatase C.ALP] using the manual techniques as 
described by Bernt and Bergmeyer (1974) and analysis of FPL 52758 and 
metabolites by t . l . c .  and Vitatron densitometry (see Chapter 2 fo r 
further details). Bile flow measurement was undertaken and samples were 
collected at hourly in tervals.
RESULTS
Clearance and metabolic studies
The to ta l excreted rad ioactiv ity  was measured fo r some of the species 
in both urine and faeces (see Table 3 .2)and showed considerable interspecies 
variation. The metabolic p ro file  of the compound was compared in twelve 
species. Of the major metabolites in urine and plasma, quantitative  
estimates are given where data is available (see Table 3 .3 ). The major 
metabolites are shown in Figure 3 .1 .Most species metabolised the compound
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Figure 3.1 FPL 52757 and Major Metabolites
readily . Although the data is largely qualitative  in nature the species 
variation in the degree and pattern of metabolism is evident. The 
compound was metabolised extensively 50-100% in the ra t, cynomolgus monkey 
and squirrel monkey. To a lesser extent in man (4-51%) and to a negligible 
degree in dogs. Most species produced the secondary alcohol ( I I )  as the 
major metabolite in urine. However, the squirrel monkey produced large 
amounts of primary alcohol ( I I I )  and no significant amounts of metabolite 
( I I ) ,  The occurrence of the ethinyl metabolite (IV) was inconsistent.
In general/ only parent compound ( I )  was found in significant amounts 
in the plasma of a ll species.Table 3.4 gives values for the plasma 
clearance of FPL 52757 in ra t , rabb it, squirrel monkey, dog and man.
Dog and man cleared the compound slowly compared with other species. The slow 
plasma clearance of FPL 52757 in the dog results in a sustained high plasma 
concentration (see Figure 3 .2 ).
Isolated perfused ra t liv e r  studies
C lin ical chemistry
Figure 3.3 shows the results obtained for perfusions 1 - 4. Back­
ground hepatic deterioration is estimated by analysis of the control 
perfusates (PI and P2). A concentration of 750yg ml  ^ FPL 52758 (P4)
in the perfusion media had l i t t l e  effect on ALT or ICDH. However, ALP
-1was elevated. FPL 52758 at lOOOyg ml (P3) produced marked elevation
of a ll three enzymes. Pretreatment with SKF 525A caused an apparent
increase in ALP when combined with a perfusion media concentration of
400vtg ml~  ^ FPL 52758 (P6). ICDH, ALT and ALP levels from the perfusion
_1
receiving FPL 52758 (400 yg ml ) alone (P5) were within control 
lim its (see Figure 3 .4 ); , ' V }r /  ' y
Bile flow
FPL 52758 reduced b ile  flow rate . SKF 525A pretreatment did not a ffec t 
this reduction (see Table 3 .5 ).
FPL 52758 and metabolite levels in the perfusate
A slight reduction in FPL 52758 metabolism following SKF 525A 
pretreatment (see Table 3 .6 ).
Table 3.4 Plasma Clearance of FPL 52757
Species Number of Animals 
Investigated
Dose, 
mg kg"
Clearance, 
ml kg" hr
*Rat 4 10 138+
*Rabbit 4 10 44+
*Squirrel Monkey 2 10 59+
Dog 1 20'
5 12f
10 13+
20 10+
35 13f
50 13+
*Man 3 approx. 1 15
+ 14Denotes clearance of the ( C )-label, Clearance values fo r the parent
compound in these species w ill be greater depending upon the concentration
of (14C) metabolites present in the plasma. Thus the values given for dog
w ill approximate to the clearance of the parent compound. The clearance
given for man is for parent compound.
*  Calculated from blood level data in Fisons Safety Evaluation F iles .
-57-
Plasma concentration (u g .m l-1 )
200
150
100 H
5 0 -
25  -
1 0 -
5 -
2 -
dog
rabbit
rat
squirrel -  monkey
0
 ------------- 1------------ r
2 A 6
T i m e  ( h )
” i
10
Intravenous infusions were given to the following species:-
ih  ® dog, 0 - - - - - - - - - - - 8  rabb it, A- - - - - - - - - - - - - - A  squirrel monkey and o----- -o ra t ,
and the subsequent levels are shown above.
1A -1
Figure 3.2 Plasma concentration of C-FPL 52757 (pg ml ) 
following an intravenous infusion of 10 mg kg ^.
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Table 3.5 Bile Flow yl hr ^
Time
(in hours)
Perfusion
(No)
Pi P 2 P 3 P4 P 5 P 6
0 - 1 500 300 250
(,K
trace 200 150
1 - 2 400 250 trace 50 150
2 - 3 400 250 trace 150 150
3 - 3| 150 ' 125 trace 100 50
Bile duct cannulated with pp 25 polypropylene tubing; b ile  drained and 
collected in a graduated LP3 tube for hourly measurement.
Table 3.6 FPL 52757 and FPL 57704 levels yg -1ml in plasma
samples from P5 and P6
Perfusion
(No)
Time
(in  hours)
P 5
FPL
57704
FPL
52757
P6
FPL
57704
FPL
52757
1 37 390 0 440
2 55 410 35 575
3 70 400 55 460
°2 80 370 50 540
Two ml perfusate samples were collected at hourly intervals from a 
sampling duct below the liv e r .
DISCUSSION
FPL 52757 was extensively metabolised and eliminated as parent compound 
and metabolites in the urine and faeces of most species. Metabolism was 
principally by a-hydroxylation of the 6-ethyl substituent. There was no 
evidence for hydroxylation of the 8-ethyl group. Hydroxylation to the 
primary alcohol (designated I I I  in Figure 3.1) was a minor metabolite in  
most species with the exception of the squirrel monkey. The dog appeared 
to be atypical being unable to hydroxylate FPL 52757 to any appreciable 
degree. The poor a b ility  o f the dog to hydroxylate a lic y c lic  or a liphatic  
carbon atoms which are readily metabolised by a number of species, including 
rodents and primates, has been noted with a number of compounds • These 
include probenecid (Dayton et e\_9 1973), bucloxic acid (G ros^t al_, 1974), 
debrisoquine (Allen e t al_, 1970), dichloro-2-methyl-l-oxo-sindanyloxy acetic  
acid (Zacchei et al_, 1978) and proxicromil (Smith, 1980). Whilst this 
seems to indicate a trend there are examples where the dog more readily  
hydroxylates a lic y c lic  and aliphatic  carbon atoms. For instance 3a, 4, 5 ,
7, 7a-Hexahydro-3-(l-methyl-5-nitro-lH-im idazol-2yl)l,2-benzisoxazole is 
extensively hydroxylated at the a lic yc lic  carbons of its  hexahydrobenziso- 
oxazole ring by the dog (Vandenleuvel et'al_, 1976). S im ilarly , one o f the 
tertiarybutyl groups of terbucromil (Augstein £ t  al_., 1976) which is related 
in structure to proxicromil and FPL 52757, is also readily hydroxylated by 
the dog (unpublished data). Recently substantial differences have been 
demonstrated between the microsomal components of the liv e r  in ra t and dog 
(Golan £ ta j_ , 1979) . The total cytochrome P-450 level o f  dog liv e r  re la tive  
to microsomal protein is about h a lf that of ra t , yet the rate o f in v itro  
0-dealkylation of 7-ethoxycoumarin in dog is more than twice that o f ra t 
re la tiv e  to microsomal protein. The types of individual cytochrome P-450 
present in dog liv e r  are therefore lik e ly  to d iffe r  substantially from those 
present in the ra t and these differences may be reflected in the substantial 
variations in carbon hydroxylation observed for FPL 52757 between species.
The ethinyl compound (designated IV) in  Figure 3.1 was found in small 
irregular amounts in some species, but more consistently in  human samples.
I t  probably arises via dehydration from the secondary alcohol. Dehydration 
has been shown to occur with other compounds, for example, quinic acid is 
converted to benzoic acid in the gut of old world monkeys (Adamson e t a l , 
1970).
The slow plasma clearance of FPL 52757 in the dog and man (see 
Table 3.4) results in a sustained high plasma concentration following 
dosing (see Figure 3 .2 ). This facto r, together with a high degree of 
hepatobiliary clearance of the parent compound in the dog may explain 
the particular sensitiv ity  of this species to the hepatotoxic action 
of the chromone. Hepatotoxicity due to FPL 52757 in the dog and 
possibly man may therefore be related to the amount of parent compound 
accumulating in the hepatobiliary system.
The isolated perfused ra t liv e r experiments, because of th e ir  
incompleteness, cannot be regarded as conclusive. However, i f  
to x ic ity  is considered to be related to drug treatment, i t  is apparent 
that FPL 52757 reduced b ile  flow and produced hepatobiliary damage. 
Evidence for chromone-induced to x ic ity  would have been more convincing 
i f  a clear dose-response had occurred. Nevertheless, even the lim ited  
data obtained provides further evidence for the high degree of 
resistance of the rat liv e r  to FPL 52757 induced-hepatotoxicity.
Additional experiments were planned to elucidate the role of metabolism in 
to x ic ity . These studies were terminated (as data accumulated from the 
in vivo studies described in Chapter two implicating the parent compound 
in hepatotoxicity) in favour of a simple novel method for the assessment 
of the hepatotoxic effect of FPL 52757 and other chromones on the ra t 
liv e r  by retrograde b ilia ry  infusion (see Chapter 5 ) and experiments 
to elucidate the physico-chemical value of chromones (see Chapter 4);
CHAPTER FOUR
The physico-chemical properties of chromones.
SUMMARY
The degree of detergency of a series of chromones is linked 
to structural properties and a detergency/structure a c tiv ity  
relationship established. .. • ,
INTRODUCTION
The results in the previous chapters implicate the parent compound 
as the hepatotoxic agent and species variation in susceptib ility  is 
explained on a toxicokinetic basis. Although these findings contribute 
towards an understanding of chromone induced to x ic ity , the actual 
mechanism of hepatotoxicity remained obscure. In th is chapter the physico­
chemical properties of FPL 52757, and a number of related chromones are 
considered. The structure of FPL 52757 suggests that i t  should have 
detergent a c tiv ity  (Schwartz and Perry, 1949). To investigate th is  
possib ility  the surfactant properties of FPL 52757 have been compared 
with a number of other chromones. Surface action could account fo r the 
hepatotoxicity of FPL 52757 i f  accumulation in the liv e r  occurred.
To complement surface a c tiv ity  data a study on the a b ility  of 
chromones to form micelles in solution is reported.
MATERIALS AND METHODS
FPL compounds and other chemicals.
FPL 55689 (6 ,8-diethyl-4-oxo-4H-l-benzopyran-2-carboxylate), FPL 52758 
(Na* salt)ofFPL 52757 (6 ,8-diethyl-5-hydroxy 4-oxo-4H-l-benzopyran-2-carboxyl 
ac id ), FPL 57704 (8-ethyl-5-hydroxy-6-(1-hydroxyethyl)-4-oxo-4H-l-benzopyran- 
2-carboxylic ac id ), FPL 58280 (6-ethinyl-8-ethyl-5-hydroxy-4-oxo-4H-l-benzo- 
pyran-2-carboxylic a c id ), FPL 57731 (4-oxo-6,8-dipropyl-4H-l-benzopyran-2- 
carboxylic acid) ,  FPL 57498 (5-hydroxy-4-oxo-6,8-dipropyl-4H-1-benzopyran-2- 
carboxylic a c id ), FPL 57579 (6,7,8,9-tetrahydro-4-oxo-10-propyl-4H-l-naptho- 
pyran-2-carboxylic ac id ), FPL 57787 (Proxicromil) (6 ,7 ,8 ,9-tetrahydro-5- 
hydroxy-4-oxo-10-propyl-4H-naptho 2,3-6 pyran-2-carboxylic acid) and FPL 
59665 (6,7,8,9-tetrahydro-5,7-hydroxy-10-propyl-4H-naptho 2,3-6 pyran-2- 
carboxylic acid) were provided by Fisons Pharmaceuticals, Loughborough, 
Leicestershire, U.K. A ll FPL compounds were more than 98% pure, th e ir  
structures were established by unequivocal synthesis confirmed by n .m .r., 
i .v .  and u.v. spectrometry (personal communication). Lauryl sulphate and 
Rhodamine 6G (benzoic acid 0-(6-ethylam ino-3-(ethylim ino-2,7 dimethyl 3H- 
xanthen-9-yl) ethyl ester monohydrochloride were obtained from the Sigma 
Chemical Company, St. Louis, M.O., U.S.A.
N.B. The structure of each of the above FPL compounds is given in the 
Results Section (Table 4 .1 ).
Surface a c tiv ity  evaluation
The surface tension of solutions of FPL 55689, FPL 52757 (or its  
sodium s a lt, FPL 52758), FPL 57704, FPL 58280, FPL 57731, FPL 57498,
FPL 57579 (Proxicromil) ,  FPL 57787 and FPL 59665 were measured at 22°C 
+ 2 C with a Du Novy tensiometer. A measure of surfactant a c tiv ity  is 
the surface pressure | ( i .e ,  surface tension of control solution of 1% 
aqueous NaHCO^  minus the surface tension of the drug-containing 
solution (Dujovne, 1975)|
C ritica l micelle concentration'(CMC) measurements
The CMC was measured by adapting a technique by Carey and Small
(1969), Rhodamine 6G was prepared as a stock solution with 1%> aqueous
- f iNaHCOg to give a fin a l concentration of 2,5 x 10 M. A range of 
concentrations (between 0 - 76 mM) of FPL 52757, FPL 57787 and FPL 58280 
wei*e prepared in Rhodamine 6G and scanned on a Varian spectrophotometer 
from 580 to 500 nm, to determine the wavelength of maximum absorption 
at room temperature.
The CMC is extrapolated from the lower break point of the plot of 
the wavelength of maximum absorption of Rhodamine 6G versus log 
concentration,
RESULTS
Surfactant properties of FPL compounds
The surface a c tiv ity  expressed as the surface pressure is given 
in Table 4.1 . FPL 57498, 57787, 57579 and 52757 had surface a c tiv ity  
effects sim ilar to that of lauryl sulphate. The major hydroxylated 
metabolite (FPL 57704), the ethinyl compound (FPL 58280), FPL 55689 and 
FPL 57731 were shown to have l i t t l e  or no effec t. From the structures 
of FPL 52757 and other chromones (Table 4 .1 ), a s tructure-activ ity  
relationship is apparent. FPL 52757 exhibited a concentration related  
increase in surface a c tiv ity , for FPL 58280 and FPL 57787 the increase 
was reversed above a c r it ic a l concentration (see Table 4 .2 ).
C ritica l micelle concentration (CMC)
The spectral maximum of the dye is plotted against the log concentrati 
of the chromone (see Figure 4 .1 ) , and the spectral sh ift which occurred 
over a range of chromone concentration is illu s tra ted . The lower break
Table 4.1 The structure and surface pressure of FPL compounds
FPL 57579
FPL 57787 
(Proxicromil)
FPL 59665
Lauryl sulphate
COOH
Compound Ri R2 R3 R4 Surface Pressure
FPL 52689 ii C2H5 H C2H5 4* (+ 3 .0 )
FPL 52757 OH C2H5 H C2H5 12 (+ 1 .0 )
FPL 57704 OH c2h. oh H C2H5 4* (+ 2.0)
FPL 58280 OH C2H4 H C2H5 6 (+ 2 .0 )
FPL 52731 H C3H7 H C3H7 6 (+ 2 .0 )
FPL 57498 OH C3H7 H C3H7 33
(+ 1 .0 )
OH
OH
C3H7
C3H7
C3H7
14 (+ 5 .0)
20 (+ 3 .0)
4* (+ 4 .0) 
30 (+ 2 .0)
The surface pressures of the FPL compounds and lauryl sulphate were
-1measured a t 1 mg ml in ]% aqueous NaHCO^ . The surface tension of 1% 
aqueous NaHCOg was 65 (+ 4 ).
*  Change in surface tension within control values.
Standard deviations from 6 readings are given in brackets.
Table 4 .2 . Additional surface pressure (dynes cnT^) measurements.
Compound
Concentrations
mg/ml
Surface pressure dynes cm  ^
FPL 52757 FPL 58280 FPL 57787 
Proxicromi
0.5 10 (+ 1 ) 3* (+ 1) 10 (+ 1)
1.0 12 (+ 1 ) 4* (+ 2) 20 (+ 1)
2.0 15 (± 1 ) 10 (± 1) 23 (+ 1)
4.0 16 (+ 1 ) 13 (± 1 ) 24 (+ 1 )
8.0 19 (± 1 ) 15 (+ 1 ) 22 (+ 1)
i—
i o o 21 (+ 1 ) 22 (+ 0) 21 (±  1)
20.0 20 (+ 3) 11 (+ 1 ) 20 (+ 2)
The surface pressure of FPL 52757, FPL 58280 and FPL 57787 was measured
"1over a range of concentrations (0.5 - 20.0 mg ml ).
The surface tension of 1 % aqueous NaHCOg was 6.5 (+ 4 ).
*Change in surface tension within control values.
Standard deviations fo r 6 readings are given in brackets.
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point a t A is taken as the arb itrary  CMC value, and gave the following 
values - FPL 52757 0.30 mM; FPL 58280 0.22 mM and FPL 57787 0.19 mM.
DISCUSSION
The structu re -activ ity /surface-activ ity  relationship of the FPL compounds.
The surface-activity of FPL compounds (having a strongly polar 
carboxyligroup at one end of the chromone nucleus and a lipoph ilic  chain 
or ring at the other end) is in agreement with that suggested by direct 
observation of the number of linear carbon atoms comprising the lipoph ilic  
portion of each molecule. The 5-hydroxyl group substituent (a t R^) .
e ffec tive ly  increases the lip o p h ilic ity  (by strong hydrogen binding 
to the adjacent keto function, i t  negates its  own polarity and that of 
the keto group) and is essential fo r surfactant properties in a chromone.
(see Table 4 .1 ). Hence the potency of the parent chromones is as follows - 
FPL 57498 > FPL 57787 > FPL 52757. The metabolites of FPL 52757, FPL 
57704 and FPL 58280 were comparatively inactive as was FPL 59665 the 
metabolite of FPL 57787. The analogues of FPL 52757 and FPL 57787; FPL 55689 
and FPL 55731 respectively, also lacked surface a c tiv ity . However, FPL 
57579, the analogue of FPL 57787, retained some of the parent compounds 
surfactant properties despite the absence of the 5-hydroxyl group. As 
a general rule either the insertion of an additional hydroxyl group into 
the lipoph ilic  region or the deletion of the original 5-hydroxyl group 
appears d rastica lly  to reduce the detergency of the parent chromones.
The surface a c tiv ity  of FPL 527^7 in solution continued to increase 
with increased drug concentration. However, th is phenomenon •‘did not hold 
for the other chromones investigated (see Table 4 .2 ).
The c r it ic a l m icelle concentration of FPL 52757, FPL 57787 and FPL 58280.
At the outset of this experiment i t  was believed that the a b il ity  of the 
chromones to form micelles would correlate with reduced surfactant and 
toxic properties. The comparatively low CMC of FPL 57787 and FPL 58280 
could explain the surface tension results obtained with increasing 
chromone concentration i f  m icelle formation reduced surface a c tiv ity .
Howeverj Chapter 5 w ill show there is no relationship between to x ic ity  
and the CMC values reported in th is chapter.
Carey and Small (1969) suggest that wavelength changes are produced by 
dye binding to micelles and as more micelles form more dye is bound, and 
the top break point is where the dye partition  is strongly in favour of 
micelles, thus the spectrum ceases to s h ift. This implies that the top 
break point represents the concentration where micelle formation is at 
its  height. Values were as follows: FPL 52757 9.4 mM; FPL 57787 12.5 mM 
and FPL 58280 5.0 mM. The smaller the above value the lower the 
concentration at which the micelle form of the chromone w ill predominate,
A correlation with to x ic ity  FPL 58280 < FPL 52737 < FPL 57787 occurs in 
a number of in v itro  tests (see Chapter 5 ), which'may'imply that the 
existence of the chromones in the largely micelle form reduces the ir  
surfactant properties and to x ic ity .
Coleman & Hoidsworth(l976)relate micelle formation to erosion and 
damage of the b ile  canalicular membrane. They suggest that as b ile  sa lt 
concentration exceeds CMC in the canalicular lumen the b ile  salts form 
micelles which withdraw lip id  from the outer face of the canalicular 
membrane resulting in membrane perturbation and loss of externally  
orientated enzymes (e.g. 5' nucleotidase and alkaline phosphatase).
In relation to chromone to x ic ity , the role of micelle formation 
remains unclear. Suffice i t  to say that thethree chromones had sim ilar 
CMC and sim ilar physicochemical properties to b ile  salts (Carey and 
Small, 1969), and lik e  these endogenous detergents the chromones can 
form micelles which may in terfere  with the plasma membrane of the 
b ilia ry  trac t in the manner postulated for b ile  salts.
In the following chapter the physico-chemical characteristics of 
the FPL compounds are related to to x ic ity , and the a b ility  of FPL 52757 
to damage the hepatobiliary trac t is investigated in both Chapters 5 
and 6.
CHAPTER FIVE
The relationship between chromone to x ic ity  and detergency
-71-
SUMMARY
The to x ic ity  of FPL 52757 in retrograde b ilia ry  infusion studies 
in ra t and in the lysis of erythrocytes in v itro  is related to the 
detergent properties of the drug. Other chromones have also been 
examined. The greater the detergent properties of the chromones the 
greater th e ir to x ic ity  in both biological tes t systems.
INTRODUCTION
In the previous chapter a detergency/structure-activity  
relationship was presented. This surface-action could account for 
the hepatotoxicity of the drug i f  accumulation in the liv e r  occurred.
To investigate th is possib ility  the to x ic ity  of FPL 52757 has been
compared with a number of other chromone compounds in erythrocyte
lysis and retrogade b ilia ry  infusion studies in ra t. The erythrocyte
lysis experiments give a measure of the actual membrane damaging
potential of each chromone. The retrograde b ilia ry  infusion studies
can be regarded as a novel method of assessing the hepatotoxic
potential of drugs, i f  the hepatobiliary system is involved in
progression of drug-induced to x ic ity . This method enables high concentrations
of a drug to be administered to the ra t liv e r  with considerable ease via the
hepatobiliary trac t thus largely avoiding metabolism.
The toxicology of FPL 52757 in the hepatobiliary trac t is of
particular interest for a number of reasons:
-  FPL 52757 was found in high concentrations (approx. 8 mg ml 
in gall bladder b ile  from dogs at autopsy (see Chapter 2).
-  Gall-bladder b ile  samples from these dogs were abnormally 
th ick, viscous and dark.
- Excretion of FPL 52757 via the b ile  duct appears to be 
saturable in dog (see the following chapter).
-  Following oral FPL 52757 treatment in dogs histopathological 
examination of liv e r  sections revealed enlarged, congested and 
damaged b ile  ducts (Chapter 2).
-  Coleman e t aj[ (1976) havesuggested that the endogenous detergent 
bile  salts cause membrane perturbation*, i t  seemsprobable that exogenous 
detergents in the b ile  may have a sim ilar and possibly more drastic  
e ffe c t.
Following retrograde b ilia ry  infusion of chromones toxicological 
assessment by measurement of b ile  flow, b ile  enzyme levels and b ile ' 
electrophoresis is complemented by conventional micro-histopathology.
These unconventional but sensitive means of assessing to x ic ity  are used 
again in the following chapter in detailed toxicokinetic studies
in dog and ra t (see Chapter 6 ). The results from Chapter 6 are 
pertinent to those presented in this chapter.
MATERIALS AND METHODS 
FPL Compounds
FPL 55689, FPL 52758 (Na+ sa lt of FPL 52757), FPL 52757,
FPL 57704, FPL 55731, FPL 57498, FPL 57579, FPL 57787 and FPL 
59665. (The fu ll  chemical names and structures are given in the 
previous chapter).
METHODS
Erythrocyte Lysis
Erythrocytes were prepared by centrifugation (2,500 x g for 10 
minutes) of freshly drawn heparinised ra t blood. The separated 
erythrocytes were washed twice by resuspension in isotonic saline 
and recentrifuged and then suspended in a volume equal to twice the 
original blood volume. Solutions (0.95 ml) in isotonic saline of 
the chromone compounds under te s t a t various concentrations were incubated 
at 37°C for 5 minutes. Aliquots (0.05 ml) of the erythrocyte suspension were 
added to the chromones, rapidly mixed and incubated at 37°C for 15 minutes. 
Incubations were terminated by centrifugation (2,500 x g for 10 min.) 
and an aliquot (0.1 ml) of the supernatant was removed, diluted with 
d is tille d  water to 1 ml and the absorption measured at 416 nm in a 
spectrophotometer (Pye Unicam SP 1800, Cambridge, England). Reference 
samples to determine the degree of lysis were produced by a suspension 
of erythrocytes in isotonic saline with no drug (0% lys is ) and in 
d is tille d  water (100% ly s is ).
Erythrocytes rather than isolated liv e r  cells were chosen as the 
model ce ll system for the reasons given by Coleman dt ^ l  (1979) in his 'studies 
on mammalian b ile  composition and its  membrane damaging properties.
Retrograde b ilia ry  infusion
The method of retrograde b ilia ry  infusion was adapted from Takada
et al ( 1976). Male Wistar ra ts , 250 g, (Charles-River, Manston, U.K.)
were anaesthetized by an fntraperitoneal in jection of phenobarbitone
-1(Nembutal, 60 mg kg ). The common b ile  duct was cannulated using 
pp 25 Portex polypropylene tubing (Fisons S cientific  Apparatus). Bile
was collected and the flow rate measured. The chromone compounds were 
dissolved in fresh ra t b ile  ( i f  they were insoluble in b ile  1% aqueous 
NaHCOg was used) and were injected (250 y l)  into the b ile  ducts followed 
by a further 250 yl of b ile , the syringe being held in place for one 
minute post-infusion. The e ffect of th is  retrograde infusion on the 
b ile  flow rate was compared with an infusion of control b ile  or 1% 
aqueous NaHCOg containing no chromone. The flow rate was measured for 
1 hr prior to infusion and two hours post infusion. Bile samples were 
analysed fo r 5 '-nucleotidase and gamma-glutamyl transpeptidase levels.
Liver damage was assessed by lig h t microscopy. Bile protein content 
was assessed by immunoelectrophoresis.
C lin ical chemistry (on b ile  samples)
Gamma-glutamyl transpeptidase (G-GT): G-GT catalyses the transfer of
the glutamyl residue from y-glutamyl-p-i n itroanilide to glycyl-glycine. The 
liberated p-n itroaniline is proportional to the G-GT a c tiv ity . The 
absorbance increase^caused by its  yellow colour can be measured at 410 nm.
A manual method was adapted from the two established techniques described 
by Rosalki (1975). Two ml of 6.25 mM L-glutam yl-p-nitroanilide in 0.1 M 
Tris with 0.05 M glycyl-glycine was mixed with 0.5 ml of b ile  (diluted  
1 in 5 ). This was incubated a t 37°C for 1 hr. The reaction was stopped 
with .1 ml of acetic acid, and solutions were read at 410 nm.
5'-Nucleotidase: 5'-nucleotidase liberates phosphate from the substrate
5’ -adenosine monophosphate (5'-AMP), The liberated phosphate is  
proportional to 5'-nucleotidase a c tiv ity .
A manual nucleotidase assay was based on the method of Jjoldsworth
and Coleman (1975). 0.4 ml of buffer cons i s ti ng of 0.25 M Tris^ 12.5 mM
MgClg and 25 mM Na K ta rtra te  (fpH 7. 8^at~~37 °Cj was mixed with 0.5 ml b ile
(diluted 1:5) and 0.1 ml of 0.05 M adenosine monophosphate, and incubated
fo r 1 hr at 37°C. 1.5 ml of 6% Trichloracetic acid was added and protein
removed by centrifugation. To measure phosphate in 2.5 ml of supernatant,
1.5 ml of 6% ammonium molybdate in 5% perchloric acid was added and le f t
-1fo r 5 min. F inally  0.5 ml of ascorbic acid (2 mg ml ) was added and 
the solution read at 700 nm a fte r  20 min.
Electrophoresis of b ile  samples: Inmunoelectrophoresis (based on the
technique of Axel senret aj_, 1973),was used to characterise b ile  proteins from 
ra t b ile  samples following retrograde b ilia ry  infusion. Agarose 1% 
was mixed with a tris/barbitone buffer pH 8 .6 , boiled gently un til
completely dissolved then maintained at 55°C. 2.5 ml agarose was run
on to a plate in a measured s tr ip , a well was cut and 5 yl b ile  sample 
was applied. A current of 80 volts was maintained across this s trip  
for 1 hr. 7.5 ml agarose containing antisera was applied before the 
next run of 12 volts overnight, which was followed by a staining with 
Coomassic B r il l ia n t  Blue R. Plasma proteins were removed from selected 
b ile  ra t samples prior to electrophoresis by conjugation on to a 
Sepharose slurry on to which anti-serum to  plasma protein had been bound 
overnight (Mullock et aj_, 1977). Bile samples were gently shaken in a tumble 
mix overnight with the slurry. Preparation of antisera was by the method 
described by Mullock eit aj[ (1977).
RESULTS
Erythrocyte lysis
Incubation of the various chromones with erythrocytes gives an 
indication of th e ir actual membrane damaging potential in terms of the 
concentrations required to lyse 5.0% of the erythrocytes (EL^q) (see Table 
5 .1 ). The potencies of the chromones to cause erythrocyte lysis correlated
d irec tly  with th e ir surface a c tiv ity  in solution. The major hydroxyl 
metabolite of FPL 52757 (contrasting with the parent compound), shows no 
membrane damaging effects under the conditions of the tes t. The pattern 
is repeated for other chromones, and metabolites.
Retrograde b ilia ry  infusion
To reproduce the effect of high concentrations of FPL 52757 and 
other chromones occurring in the b ilia ry  system, compounds were 
introduced into in tact anaesthetised rats by retrograde infusion into the 
b ile  ducts. The to x ic ity  of each of the compounds was then assessed 
according to impairment of b ile  flow and the degree of liv e r  damage. 
Infusion of surfactant chromones produces dose-related cholestasis 
(see Table 5.2) (e .g . FPL 52757 infusion at 5 mg, 7.5 mg and 10 mg gave 
23%, 54% and 100% decreasesin b ile  flow respectively) which is accompanied 
by dose-related hepatocellular and bile-duct damage (see Table 5 .2 ).
D irect damage has been assessed by conventional lig h t microscopy of 
l iv e r  sections. Both b ilia ry  flow impairment and the degree of necrosis 
correlated with the surfactant a c tiv ity  of the chromone compounds.
Table 5.1. Aqueous surface a c tiv ity  (detergency) and erythrocyte 
lysis for a series of chromones
Compound El -1 50 mg ml 1 Degree of surface a c tiv ity  (Detergency)
FPL 55689 > 2 slight
FPL 52757 1.05 moderate
FPL 57704 > 2 slight
FPL 58280 not measured slight
FPL 55731 1.5 sligh t
FPL 57498 0.17 high
FPL 57579 1.02 moderate
FPL 57787 0.18 high •
FPL 59665 > 2 V s ligh t
Lauryl sulphate 0.04 high
EL^ q (concentration to lyse 50% of the erythrocytes in test solution) 
value given alongisde the degree of surface a c tiv ity  (data derived from 
previous chapter). The erythrocyte was incubated with solutions of 
compound under test for 15 min. at 37°C. Lysis was assayed by absorption 
a t 415 nm.
(N.B, Lauryl sulphate is a compound with known detergent properties)
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FPL 52757, in company with the other surface active chromone 
(FPL 57498) and lauryl sulphate, markedly impaired b ile  flow and 
damaged the b ilia ry  system and surrounding hepatocytes. The remaining 
chromones, including the major hydroxyl metabolite of FPL 52757 
(FPL 57704) and the ethinyl compound (FPL 58280) showed no effect 
(see Table 5 .2 ). Qualitative and quantitative data on hepatobiliary 
damage was obtained by measurement of 5 '-nucleotidase and G-GT levels 
and immunoelectrophoretic studies.
B ilia ry  enzyme analysis
Retrograde infusion of FPL 52757 into the b ile  duct of the ra t 
produced no change in 5 '-nucleotidase levels in subsequent b ile  samples. 
G-GT showed a significant dose-related elevation (see Table 5 .3 ).
Immunoelectrophoresis of b ile  samples
Bile against b ile-protein anti sera: Plates 1 and 2 show the results 
obtained following 2-dimensional electrophoresis of b ile  samples in 
the presence of b ile  protein antisera (2%). The b ile  sample on plate 
2 was obtained following in tra b ilia ry  retrograde infusion of FPL 52757 
at 5 mg. Plate 1 is a control. The test sample was shown to contain 
greater amounts of protein.
Bile against b ile-protein  and serum-protein anti sera: Plates 3 and 4 
show the results obtained following 2-dimensional electrophoresis of b ile  
samples in the presence 0f  b ile  protein antisera (2%). Plates 5 and 6 
show the results obtained following 2-dimensional electrophoresis of 
bile  samples in the presence of 2% rabbit immunoglobulins to ra t serum 
protein. The b ile  samples on plates 4 and 6 were obtained following 
retrograde infusion of FPL 52757 at 7.5 mg. Plates 3 and 5 were obtained 
from control b ile  samples. Plates 3 and 4 confirm the results obtained 
above. Comparing the two experiments a dose-response increase of protein 
in the b ile  is evident. Bile run against antisera to plasma proteins 
indicates a massive leakage of serum proteins into the b ile .
Conjugated and unconjugated b ile  experiment: The following two dimensional
electrophoresis plates were run, using b ile  samples obtained a fte r  b ilia ry  
retrograde infusion of 5 mg FPL 52757:
Table 5.3. S'-Nucleotidase and gamma-glutamyl transpeptidase
a c tiv ity  in b ile  following retrograde b ilia ry  infusion
of FPL 52757
Total infusion 
dose in mg.
5 '-Nucleotidase _-] 
ymol product formed min
G-glutanyl transpeptidase 
yg product formed hour
0 5 (+ 1.2) 3.9 (+ 1.3)
1.25 7.2 (+ 2 .0 ) 5.6 (+ 2.5)
2.5 7.3 (+ 1 .0 ) 7.0 (+ 2.7)
5.0 5.5 (+ 2.2) 9 .3* (+ 4 .3)
10.0 not measured 12.5* (+ 6 .0 )
Each result represents the mean of at least fiv e  samples. 
Standard deviation for each result is given in brackets.
^Results d iffe r  from control p > 0.02.
Plate 1 Control B i le .
-Plate 2 B ile  fo llow ing RBI o f  FPL 52757 (5 mg)
B ile  against b i le -p ro te in  anti sera
%
Plate 3 Control B ile
Plate 4 B ile  from RBI o f  FPL 52757 (7.5 mg)
■ 'ilje  against b i le  serum-protein a n t iw a
Plate 5, Control B fle ,
P la te  6. B ile  from RBI of FPL 52757 (7.5 mg)
Plate 7. Bile run against ra t anti-sera to plasma protein (2%).
Plate 8. B ile against antisera to b ile  proteins (2%).
Plate 9. Conjugated b ile  against anti-sera to b ile  protein (2%)
Plate 10. Conjugated b ile  against anti-sera to b ile  canalicular 
membrane (5% ).^
Plate 11. Conjugated b ile  against ra t anti-sera to plasma protein (2%). 
Analysis of plates showed massive leakage of plasma protein. Plate 8 showed 
a low IgA component. The apparent removal of the secretory component from 
the b ile  run against a n ti-b ile  anti-sera further indicates severe damage to 
hepatocyte function. There was a complete absence of protein (from canal­
icu lar membrane) on plate jo t  The presence of plasma proteins in plate d  
indicated that to ta l removal during conjugation was not achieved.
DISCUSSION
In the previous chapter the physico-chemical properties of the 
chromones were compared and a 'detergency/structure-activity ' 
relationship is established. The to x ic ity  of the FPL compounds, assessed 
by the methods described in this chapter, is in agreement with that 
suggested by the degree of detergency of each compound. The novel method 
fo r assessing hepatobiliary to x ic ity  allowed the lik e ly  e ffec t of FPL 
52757 in the dog to be reproduced in the ra t, since the hepatobiliary  
trac t of the dog is lik e ly  to be exposed to high concentrations of 
FPL 52757 following oral dosing. (This concept is verified  in the next 
chapter). The retrograde b ilia ry  infusion allows the hepatobiliary  
damaging potential of FPL compounds to be compared in a specific manner 
in a convenient small animal species.
Analysis of b ile  samples obtained following retrograde b ilia ry  
infusions of FPL 52757 showed a dose-related increase in G-GT w hilst 
5'-nucleotidase levels remained constant (see Table 5 .3 ). Since G-GT 
and 5*-nucleotidase are marker enzymes for ce lls  lin ing the b ilia ry  
ductules and ducts (A!bert et cH, 1964; Roslaki, 1975) and the b ile  canal­
icu lar membranes (Toda et a l ,  1964; Rosalki, 1975) respectively, i t  is 
apparent that FPL 52757-induced damage in th is  study was restric ted  to 
the b ile  ducts and ductules. This contrasts with a previous study in ra t  
(Nekae et 1977) where retrograde infusion of another surfactant 
(Triton X-100) caused 5'-nucleotidase elevation.
*B'1$nk plate pot included,
Conjugated and unconjugateo DiJe experiments
Plate No.7. B ile  fo llow ing RBI FPL 52757 (5 mg) 
against an ti-sera  to plasma p ro te in .
Plate Mo.8. B ile  fo llow ing RBI FPL 52757 (5 mg) 
against b i le  prote in  an ti-se ra .
•Conjugated and unconjugated b i le  experiments
Plate No.9. Conjugated b i le  fo llow ing RBI FPL 52757 (5 mg) 
against an ti-se ra  to b i le  prote ins.
# v - . .  ' \  6 ?
.  -V
X
No 11 ‘Conjugated b i le  fo llow ing RBI FPL 52757 (5 mg) Plate no. . a n t i_sera tQ plasma p ro te in .
The infusate was maintained in place for 15 min. compared with 
only 1 min. in the current study. This difference in experimental 
conditions probably allowed the surfactant to penetrate further up 
the b ilia ry  tract and a ffec t the canalicular membrane in the Nekae 
study. The lack o f an e ffec t on the b ile  canaliculi in this study 
was verified  by 2-dimensional immunoelectrophoresis of b ile  against 
anti-sera to b ile  canalicular membranes. The absence o f protein bands 
on this plate indicated a complete lack of protein derived from b ile  
canalicular membranes. These enzymes and electrophoretic results may 
be viewed as evidence for the s ite  specific nature of 5'-nucleotidase.
In general the electrophoretic results demonstrated a massive 
leakage of serum proteins into the b ile  following retrograde b ilia ry  
infusion o f FPL 52757. Leakage o f such large amounts sabotage attempts 
to completely remove the serum proteins, and masked changes in other 
specific b ile  proteins.
The liv e r  damage produced by retrograde b ilia ry  infusion clearly  
showed that the more surface active chromones lik e  FPL 52757 have the 
potential to damage both the b ilia ry  system i ts e l f  and the surrounding 
hepatocytes. However, these studies were conducted with high 
concentrations o f compound introduced as a bolus.. The 'in s u lt' to the 
b ilia ry  system a fte r  oral or i . v .  administration is lik e ly  to involve 
exposure to the compound at lower levels for longer periods. Nevertheless, 
the retrograde infusion toxicology is validated in view o f the sim ilar  
pattern of FPL compound to x ic ity  established in the erythrocyte lysis  
experiments. Further validation is  provided by the 'hepatobiliary  
toxicokinetic' studies in dog and ra t in the following chapter and the 
observation that levels of up to approximately 8 mg ml”  ^ o f FPL 52757 
have been found in the gall-bladders of dogs following multi dose oral 
treatment.
CHAPTER SIX
The hepatobiliary toxicokinetics of FPL 52757 in ra t and dog
-87-
SUMMARY
Toxicokinetic studies in dog showed that intravenous infusion of
_1 _1
FPL 52757 at 4, 8 and 12 mg kg hr for 2| hours resulted in increased 
b ilia ry  excretion of alkaline phosphatase (up to 17-fo ld ), gamma-glutamyl 
transpeptidase (up to 9 -fo ld ), and 5 '-nucleotidase (up to 13 fo ld ) which 
paralleled the b ilia ry  concentration of FPL 52757 (up to 1.3 mg ml~^) and 
was accompanied by alterations in b ile flow, jhe excretory mechanism of 
FPL 52757 into the b ilia ry  trac t was shown to be saturable and could 
result in high hepatocellular drug concentration and subsequent liv e r  
damage. In a paralle l study in ra t ,  sim ilar early indications of a 
potential hepatotoxic e ffect did not occur following an intravenous bolus
. . i
of 50 mg kg FPL 52757 and the study demonstrates yet again the high 
degree of resistance of this species to FPL 52757-induced hepatotoxicity.
INTRODUCTION
Previous to x ic ity  studies have demonstrated that FPL 52757 {6,8- 
diethyl-5-hydroxy-4-oxo-4H-T-benzopyran-2-carboxylic acid) is hepato- 
toxic to the dog but not the ra t following oral dosing (see Chapters 
.1 and 2). Centrilobular necrosis occurs in dogs accompanied by some 
damage to b ile  ducts. The ra t is protected by fast metabolism and 
elimination of FPL 52757 whereas the clearance from the dog is slow 
compared with other species (see Chapter 3) and high concentrations of 
FPL 52757 have been found in the b ile  contained in the gall-bladder 
at autopsy. FPL 52757 has been shown to be a detergent (see Chapter 
4) and its  to x ic ity  is related to its  detergent properties (see 
Chapter 5). Elevation of b ile  enzymes have been reported following 
oral treatment with b ile  salts in man (Bode et cH, 1973)
and following retrograde b ilia ry  infusion of FPL 52757 in the ra t  
(see Chapter 5). The objectives of th is study were to gain further 
information on the pharmacokinetics of FPL 52757 in the dog and ra t 
following intravenous dosing and to re la te  drug levels in blood and 
b ile  to early physiological and pathological drug-induced changes in 
the hepatobiliary trac t. Attempts were made to slow the rate of metabolism 
and clearance of the chromone in rats by pretreatment of animals with the 
metabolic inh ib itor SKF 525A,
MATERIALS AND METHODS 
Materials
FPL 52758 (Na+ s a lt of FPL 52757) was provided by Fisons Pharmaceuticals 
(Loughborough, Leicestershire, U .K .). SKF 525A was provided by Smith,
Kline and French L td ., (Welwyn Garden C ity , Hertfordshire, U .K .).
Hepatobiliary toxicokinetics of FPL 52758 in beagle dogs.
Three male dogs (12-16.6 kg) were anaesthetized intravenously with 
Sagital and by inhalation of halothane. The b ile  duct of each was 
cannulated (3 mm Portex polyethylene tubing, Fisons S c ien tific  Apparatus, 
Loughborough) for sample collection a fte r the gall baldder had been 
ligated. The ureters were cannulated (2 mm Portex tubing) for urine 
collection , and an additional 2 mm cannula was inserted in the femoral 
vein (2 mm Portex tubing) for blood sampling. FPL 52758 in 0.9% aqueous
NaCl was given by i .v .  infusion to individual dogs over a period of 
2\ hours. Bile samples (every 15 min.) and urine and blood samples 
(every 30 min.) were taken prior to , during and 2 hours post-infusion 
of FPL 52758. Three dogs were treated with doses of 4, 12 or 36 mg 
kg*  ^ hr~  ^ respectively.
Hepatobiliary toxicokinetics of FPL 52758 in the r a t .
Six male rats (350 g Fisons House stra in ) were anaesthetized i .p .  
with Sagital. The femoral vein, carotid artery and b ile  duct of each 
were cannulated (pp 25 Portex tubing) fo r i .v .  dosing, blood sampling 
and b ile  sample collection respectively. FPL 52758 in 0 .91 aqueous 
NaCl was given as an i .v .  bolus injection to fiv e  animals. Four 
received SKF 525A in 0.9% aqueous NaCl i .p . 30 min before FPL 52757. 
Each individual treatment is oultined.below:-.
Table 6.1. The dosing schedule for the six rats in the 
FPL 52758 hepatobiliary toxicokinetic study
Rat Number Treatment 
FPL 52758 SKF 525A 
mg kg" i .v .  mg kg" i .p .
1 20 -
2 20 50
3 20 50
4 30 50
5 ■; 50 50
6
- no treatment.
In both studies the following analyses were undertaken using 
conventional techniques or methods described previously unless otherwise 
stated: a) concentrations of drug in plasma, b ile  and urine; b) b ile  
flow rate; c) alkaline phosphatase (ALP), 5 '-nucleotidase* and gamma- 
glutamyl transpeptidase*(G-GT) a c tiv itie s  in b ile ; d) immunoelectro- 
phoresis of b ile  samples*; e) serum glutamate dehydrogenase (GLDH)*; 
f )  serum alanine aminotransferase (ALT)* and serum alkaline phosphatase 
(ALP). (* Assay undertaken on dog b ile  samples only).
A Boehringer test k it  was used in conjunction with a Vitatron  
automatic analyser AKED with a 410 nm interference f i l t e r  (Szasz,
1969) for G-GT measurement.
RESULTS
Hepatobiliary toxicokinetics of FPL 52758 (the soluble Na+ sa lt 
of FPL 52757) in the dog.
No metabolites of FPL 52757 were detected in any sample of plasma, 
urine or b ile  analysed. The parent compound was found in the plasma 
and b ile , but not in the urine. Chromone concentrations o f about 1 mg 
ml”  ^ were attained in the b ile  o f a ll  3 dogs (see Figure 6 .1 ).
The b ile  flow was accelerated by i .v .  infusion of FPL 52758; 
within 30 mini of dosing the flow rate was increased by 50-200% in
the 3 dogs. This increase was maintained throughout the experiment
-1 -1 -1 -1at the lowest dose (4 mg kg hr );  a t 12 mg kg hr the flow rate
slowly decreased to control levels; at the highest dose (36 mg kg  ^ hr ^) 
the decline was rapid and the rate eventually became slower than 
controls (see Figure 6 .1 ).
The enzyme ALP, G-GT and 5'-nucleotidase excreted in the b ile  were 
a ll increased, a fte r  an in i t ia l  f a l l , in the 3 dogs. The increase in 
these enzymes paralleled the chromone concentration in the b i le ,  and 
the onset o f release o f these enzymes depended on the dosage administered 
(see Figure 6 .2 ). Some serum enzymes were s lig h tly  raised e.g . ALP was 
increased 2-fold in a ll 3 dogs. Other serum enzymes were near normal with 
the exception of AST (2-fo ld  increase) and GLDH (9-fo ld  increase) which 
was s ign ifican tly  raised in the dog receiving the highest dose (see 
Appendix 3, Tables 1 -3 ).
The rate of b ilia ry  excretion o f FPL 52757 did not vary much with dose 
(see Table 6.2) and as only 19% was excreted in 4| hours.even,at . 
the lowest dose i t  is lik e ly  that the excretion rates recorded represent 
the maximum excretion rate (V ) .
U lC l/\
The percentage o f the dose given in the tissues at d iffe re n t times 
during intravenous infusion o f FPL 52757 was estimated by subtracting the 
amount excreted plus the amount in the plasma from the to ta l quantity 
of drug given.
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Table 6.2 The effect of d iffe ren t doses of FPL 52758 administered
by intravenous infusion on the rate of b ilia ry  secretion 
of the drug from the dog
FPL 52758 , 
(mg kg hr )
Dose of Excretion rate*
(mg hr"1 kg"1)
Amount of drug 
found in b ile  
(% dose)**
4 0.43 19.2
36
12 0.51
0 . ^
7 .?
1.4
* Excretion rate -  Total amount of drug excreted in the b ile  ‘
Dog wt. x duration of collection period i
* *  Amount of drug = Total excreted in t he b ile  x 100
found in the b ile  {%) L)ose given —
The to ta l amount in the tissues was calculated from the product of the plasma
concentration at time ( t )  and the volume of in it ia l  d ilu tion  (VID) (see
Table 6 .3 ). The apparent volume of distribution at a given time was
calculated from:
Extrapolation from the line  of best f i t  gave the volume of in it ia l  d ilution  
(VID) (see Table 6 .3 ).
Immunoelectrophoresis of dog b ile  samples.
Two dimensionsional electrophoresis of dog b ile  samples in the 
presence of anti-sera to dog: serum protein{6%) showed that d ilu tion  of 
b flia ry  protein occurred at chloresis. Plates 1 - 4 illu s tra te  the 
effect with b ile  samples from the top dose dog. Similar results were 
obtained with the other dogs. The time in relation to the s tart of the 
infusion and the volume of the sample is given adjacent to each plate.
Hepatobiliary toxicokinetics of FPL 52758 (the soluble Na+ sa lt of 
FPL 52757 in the r a t .
Early indications of a potential hepatotoxic e ffec t, such as an 
alteration  in the b ile  flow and enzyme levels did not occur in the ra t  
following an i .v .  bolus of FPL 52758 (of up to 50 mg kg"1) with 
concomitant SKF 525A treatment. The b ile  flow was approximately 
20 (+ 5) |a.1 min in a ll  animals. B ilia ry  ALP levels did not vary 
greatly and there was no correlation with either the dose given or
Total amount injected (mg) -  total amount excreted (mg)
Plasma concentration mg ml ” x Dog body wt in kg
C ontinued  p . " 97
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Immunoelectrophoresis o f  dog b i le  samples.
Two dimensional electrophoresis of dog b ile  samples in the presence 
of anti-sera to dog serum protein (6%) showed that dilution of b ilia ry  
protein occurred at chloresis. Plates 1-4 illu s tra te  the e ffec t with 
b ile  samples from the top dose dog. Sim ilar results were obtained from 
the other dogs. The time in relation to the s ta rt of the infusion and 
the volume of the sample is given adjacent to each plate.
v s .  4 / .
PLATE 1
(Time -0 hr) 
Volume 2.4 ml.
a|/io7%o PO * j; ,
vs. 6 / A-fcO* £
PLATE 2
(Time 0- I  hr) 
Volume 3.6 ml.
/ \
2#/* ©/to COCrTobhe I 10 
i ' / . f i - P 0 4 - S
PLATE 3
I H  ( . U . - l J h r )
Volume 2.4 ml
Js&
H
I  \
The resu lts  on Plates 1 and 3 are derived from b i le  samples o f  equal 
volume. A higher concentration o f  b i l i a r y  pro te in  is  present in  
Plate 3 b i le .
A*
PLATE 4
(Time 2 i , - 2 j  hr) 
Volume 1.3 m l.
I
The highest concentration o f b i l i a r y  prote in  coincides w ith  a 
reduction in  b i le  volume (see Plate 4).
chromone levels in the b ile . B ilia ry  ALP levels fluctuated between 
40-90 IU and the chromone reached a maximum b ilia ry  concentration 
of 500 yg ml”  ^ but this concentration was short-lived (approximately 
20 min.) and occurred only in the ra t receiving the highest dose with 
SKF 525A pretreatment (see Appendix 3 9 Tables 3.4 to 3 .6 ).
DISCUSSION
Hepatobiliary toxicokinetics in the dog
The concentrations of FPL 52757 in gall bladder b ile  (5-8 mg ml"^) 
was higher than that found in primary excreted b ile  (approx. 1.0 mg ml~  ^
as was expected, and the gall bladder concentrates hepatic b ile  some 
10-fold (Diamond, 1965) The concentration o f FPL 52757 in the b ile  
showed a close correlation with the release of ALP, G-GT and 5 '-  
nucleotidase into the b ile , and immunoelectrophoresis demonstrates an 
increased amount of b ile  protein (ml“^) is  present following FPL 52757 
infusion (see Plates 1 and 3 ). Since a ll three enzymes in the b ile  
were increased i t  is lik e ly  that the chromone affected the cell lining  
the whole o f the b ilia ry  tra c t, as 5 '-nucleotidase and G-GT are marker 
enzymes for b ile  canaliculi membranes (Hoidsworth and Coleman, 1975; 
Mullock, 1977) and ductal membranes respectively (Rosalki, 1975).
Sim ilar enzyme increases in ra t b ile  have been produced by retrograde 
b ilia ry  in jection o f FPL 52757 (see Chapter 5 ), of other surfactants 
(Nakae ejt 1977) and following treatment with b ile  salts (Bode e t a l ,
1973) /  . Dujovne (1977) suggests-that for drugs
which are excreted in b ile , surfactant a c tiv ity  could affect the integri 
of hepatocellular canalicular membranes and exert toxic e ffec ts , and 
surface ac tiv ity  has been shown to be correlated with hepatotoxicity 
in  numerous other compounds (Dujovne, 1978; Yasuhara e t al_, 1979; and 
Dujoyjne et a l,  1977). The surface a c tiv ity  of FPL 52757 has been 
demonstrated (see Chapter 4 ), and its  a b ility  to act in the manner 
suggested by DujoVne has now been ve rifie d .
The results in Figures 6.1 and 6.2 illu s tra tes  that there was an 
apparent threshold concentration o f approx. 500-600^ ml”  ^ below which 
release of enzymes into b ile  remained at near normal levels , above this 
level enzyme release escalated. The chromone w ill be active a t these 
sites as i t  w in  be available as 'fre e ' drug. Normally i t  is more than 
99$ bound to proteins at concentrations up to 300 yg ml"'* in plasma
from dog. The major route of elimination in the dog is unchanged 
material in the b ile . B ilia ry  excretion of anionic material involves 
an active transport mechanism situated at the hepatocyte membrane, which 
w ill enable attainment of the high drug concentrations' in the b ile .
Hence, in i t ia l ly  the canalicular membrane and at a la te r stage the 
ductal membrane of the b ilia ry  tract in dog w ill be exposed to high 
concentrations of the free chromone.
Under normal conditions, the liv e r  has the a b ility  to secrete high 
concentrations of naturally-occurring detergent b ile  salts into the 
b ilia ry  trac t without damaging i ts e lf .  This has been explained (Coleman 
et al_, 1977) as follows: b ile  salts are present in extremely low 
concentrations inside hepatocytes and are pumped out by active transport; 
as the b ile  sa lt concentration in the b ile  canaliculus approaches or exceeds 
m icellar lev e l, materials are removed from the outer face of the plasma 
membrane, but do not result in su ffic ien t damage to cause leakage of 
in tra ce llu la r m aterials; the health of the membrane of the outer surface 
of the canalicular and other duct cells is maintained by continuous 
biosynthetic repair mechanisms. I t  seems lik e ly  that the presence of 
the chromone in the b ilia ry  trac t leads to a situation where the damaging 
effects overtake the repair mechanisms. The chromone in i t ia l ly  increases 
then decreases b ile  flow. Immunoelectrophoresis shows that during chloresis 
proteins in the b ile  are diluted. As cholestasis develops the b ile  proteins 
become concentrated by an amount disproportionate to the reduction in b ile  
volume.
Since fo r a ll  3 doses of FPL 52758 the maximum excretory rate of the 
chromone into the dog b ile  was sim ilar (see Table 6.2) and independent 
of the dosage given, i t  is concluded that the excretory mechanism for the 
chromone into the b ile  is saturable. This important finding revealed that
the Vmav fo r excretion into the b ile  fo r a ll 3 dose levels was approx.max n _ rj _ -1 n
0.5 mg kg hr" (equivalent to 12 mg kg day" ). Saturation of the 
excretory mechanism for FPL 52757 leads to tissue accumulation (see Table 
6 .3 ). Coincident with this phenomenon the apparent volume of d istribution  
(Table 6.3) increases markedly with time, at the highest dose. The larger 
increase in at the top dose may be due to saturation of protein binding 
leading to a greater tissue distribution,including the l iv e r . Estimates 
of the amount of the chromone which is lik e ly  to accumulate in the tissue 
(see Table 6,3) show that there was a non-linear increase in the amount
accumulated at the top dose. This agrees with the data on percentage
recovery (see Table 6.2) of the drug and its  apparent volume of d istribution.
Much of this accumulation is lik e ly  to have been in the liv e r , the primary
target organ fo r the compound in the dog. Such an uptake, followed by
excretion via the b ile  without reabsorption from the gut probably explains
the lack of compound in the urine. Although hepatocellular damage in
the dog was s light in the present study, repeated-dose to x ic ity  studies
in the dog showed extensive hepatocellular damage. This is understandable
- 1 - 1in view of the maximum b ilia ry  excretion of approximately 12 mg kg day 
in dog which would lead to accumulation of drug in the liv e r  when the daily  
dose exceeded this rate.
Hepatobiliary toxicokinetics in the r a t .
The metabolic inh ib itor SKF 525A had only a partia l e ffec t on FPL 
52758 metabolism in the ra t. I t  had been anticipated that a considerable 
inh ib ition  of metabolism would occur resulting in the elevation of 
chromone concentrations in b ile  and plasma to the extent that to x ic ity  
could be observed in the ra t. This, however, was not the case and the 
study demonstrates yet again the high degree of resistance of this 
species to the hepatotoxic effects of th is chromone,
The fin a l hypothesis for the mechanism of the chromone hepatotoxicity 
and the species anomalies in pharmacokinetics which results in the species- 
specific to x ic ity  w ill be further developed in the fin a l chapter.
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CHAPTER SEVEN 
SUMMARY AND CONCLUSIONS
THE MECHANISM OF FPL 52757 XKDUCED HEPATOTOXICITY 
Original hypothesis versus fin a l hypothesis
At the outset of th is project the original favoured hypothesis for 
the mechanism of FPL 52757-induced hepatotoxicity was that: "The hepato- 
to x ic ity  of FPL 52757 results from metabolic activation of parent 
compound to a hepatotoxic reactive metabolite which can bind to v ita l 
hepatocellular constituents causing cell death". The current and fin a l 
hypothesis is as follows: "The hepatotoxicity of FPL 52757 is due to an 
accumulation of parent compound in the liv e r  and hepatobiliary system, 
and i t  is a combination of the in trin s ic  detergent properties of the 
drug, its  pharmacokinetics, and species anomalies in metabolism which 
result in the species-specific to x ic ity" .
The early investigations to elucidate the mechanism of hepatotoxicity 
set out to verify  the original hypothesis (Chapter 2), These special - 
studies fa iled  to implicate reactive metabolite involvement. This, 
coupled with pharmacokinetic data revealing that species resistant to 
FPL 52757-induced to x ic ity  rapidly metabolise and excrete the chromone 
(Chapter 3) implicated the parent compound as the hepatotoxic agent. 
Chapters 4 and 5 demonstrate that detergency is related to to x ic ity  and 
that FPL 52757 is more detergent and toxic than its  metabolites. In 
Chapter 6 the presence of the chromone in the hepatobiliary trac t is 
closely correlated with the incidence of hepatotoxicity in the dog, and 
hepatobiliary excretion is shown to be saturable.
The pattern of FPL 52757 hepatotoxicity does not f i t  into the 
classical schemes for mechanisms of to x ic ity . Most toxicants act either 
by acute lethal in jury or through autoxidation via free radicals. In 
acute lethal injury energy starvation leads to fa ilu re  of the "sodium 
pump" and to cell death. Autoxidation via free radicals leads f i r s t  to 
glutathione depletion then oxidative damage of ce llu la r membranes.
This classic type of to x ic ity  is described fu lly  
in Chapter 1 as i t  ties in with the original hypothesis for FPL 52757- 
induced hepatotoxicity.
Drug detergency and toxic ity
Following verifica tion  o f a structure-activ ity  relationship for 
a series of chromones i t  became apparent that the hepatotoxicity of 
FPL 52757 was probably related to its  detergent properties. This is 
a comparatively l i t t l e  known mechanism of drug-induced to x ic ity  despite 
work in  the fie ld  for a number o f years, explaining the membrane 
damaging e ffec t of a number o f drugs and endogenous compounds (see 
Table 7 .1 ). In this thesis and in these previous reports, the degree 
of detergency of a group of compounds is related to to x ic ity  in v it ro , 
providing evidence for a probable mechanism of in vivo to x ic ity .
Table 7.1 Previous reports of to x ic ity  related to detergency
Drug or group of compounds Reference
Dialose Plus (a laxative) ; i .
Erythromycin derivatives 2, 3, 4 , 5 and 15.
Oral contraceptives 6.
Bile salts 3, 7, 8, 9, 10, 11, 12, 
13, 14.
Chlorpromazine 3, 5, 15 and 16.
Tricyclic  antidepressants 7 and 16.
1. Dujovne and Shoeman (1972);2. Dujovne (1975); 3. Dujovne (1978);
4. Dujovne (1978); 5. Dujovne jet al_ (1977a); 6. Dujovne and Pentikainen 
[1973); 7. Dujovne e jt^ [  [1977b); 8. Dujovne (1977); 9. Coleman and 
Holdsworth (1976); 10. Holdsworth and Coleman (1976); Coleman e t a l , 
(1976); 12. Vyvoda ejt al^  (1977); 13. Coleman e t ail,, (1979); 14. B illington  
et _al_ (1980); 15. Dujovne and Salhab (1980); 16. Salhab £ t  aV (1979a);
17. Salhab e t a l  (1979b), 18. Yasuhura et .art (1979).
A dose related increase in detergency and in  vivo and in v itro  
to x ic ity  has been observed with FPL 52757 (see Chapter 4 ) . The effects  
on b ile  flow and the erosion o f membrane cells lin ing the b ile  
canaliculi and ductules may be related and can be envisaged in  three 
stages.
Membrane a lteration  as a hypothetical basis for chromone-induced
liv e r  injury
Stage 1: Modification of Membrane: The chromone passes into b ile  ducts 
by active transport, modifying the membrane in tran s it to allow increased 
permeability, thus increasing b ile  flow. The duration of this stage 
decreases with dose, e.g.
Dog 1 - 36 mg kg~^  hr~^; 0 - |hr of the experiment
- 1 - 1Dog 2 - 12 mg kg hr ; 0 -  2hr of the experiment
-1 -1Dog 3 - 4 mg kg hr ; 0 -  4hr of the experiment.
There is l i t t l e  indication of severe b ilia ry  tract damage during this
stage. B ilia ry  enzyme levels are near normal and electrophoretic
evidence shows d ilu tion  of b ile  protein at th is stage (see Chapter 6,
Plates 1 and 2).
Stage 2: Mediation of Membrane Damage: The)cholere t ic |effect of the drug 
is transient. The increased drug presence in the membrane and/or 
progressive damage, reduces thejcholeresis1, which further enhances erosion 
of membrane cells lin ing the b ilia ry  trac t as the drug becomes more 
concentrated in the b ile . At this stage the compound is s t i l l  being
transported into the b ile  at the same approximate rate , hence the chromone
concentration increases in the b ile  to higher levels which coincides 
with an escalation of b ile  canalicular membrane damage. B ile flow 
continues to decline a fte r th is stage and the decline does not appear 
to correlate with the concentration of drug in the b ile ; i t  may relate  
to the concentration in the b ile  canalicular membrane and surrounding 
hepatocytes. The duration o f stage 2 is as follows:-
Dog 1 - 36 mg kg  ^hr~^; H  - 2?hours
Dog 2 - 12 mg kg”  ^hr"^; 2 - 4-|hours
Dog\3 - 4 mg kg"l hr"^; stage 2 is not reached at th is dose.
During this stage enzyme release escalated and electrophoretic evidence 
shov/s an increase of b ilia ry  protein (per m i l l i l i t r e )  in the b ile .
Despite a normal or greater than normal b ile  flow rate (compare Plates 
1 and 3 in Chapter 6).
Stage 3: Maceration of the Bile Canalicular Membrane: Bile flow continues
to decline u n til i t  is below normal levels, correspondingly the drug 
concentration in the b ile  rises. This exacerbates the damage and eventually
the b ile  flow completely stops as the architecture of the b ilia ry  tract 
has become irre trievab ly  injured, leading to escalating damage to the 
b ile  ducts canaliculi and surrounding hepatocytes as the compound continues 
to accumulate in the liv e r . The duration of stage 3, which is only reached 
in dog 1 (36 mg kg“  ^ hr“1) is from f to 3 hours.
Electrophoretic evidence shows that a massive increase in b ilia ry  
protein coincides with a reduction in the volume which appears to be 
disproportionately greater than can be accounted for simply by the 
reduction in b ile  volume (see Chapter 6, Plates 1 and 4).
The pattern of enzyme release into the b ilia ry  trac t following oral 
dosing in dog was d ifferen t from that obtained in rat following retrograde 
b ilia ry  infusion. This probably reflects  damage to the whole of the 
b ilia ry  trac t following oral dosing, whilst following retrograde b ilia ry  
infusion the penetration of the toxicant is lim ited.
Bfle sa lt dependent choleresis j
An a lternative hypothesis might also account for the chromone-induced 
Icholeresis;, Since the chromones are structually sim ilar to b ile  salts i t  
is possible that a build up of drug in the b ile  stimulates b ile  s a lt 
dependent secretion leading to1 choleresis^
Conceivably both membrane permeability a lteration  and b ile  sa lt 
dependent secretion act synergistically , un til more drastic b ile  
canalicular and duct membrane alterations counteract those effects to 
produce cholestasis , i t  is recognised that the interactions between
in itia tin g  processes and consequences may reinforce each other making 
interpretation of the progression of events d i f f ic u lt .  Nevertheless, 
i t  seems lik e ly  that cholestasis accompanies and accentuates the 
hepatotoxic effect on the liv e r .
The response of the hepatobiliary trac t to endogenous and exogenous 
detergents
Although both the species-variation to chromones and th e ir varying 
hepatotoxic potential are explained in th is thesis, certain anomalies 
raise the following fundamental questions. Why is the b ilia ry  trac t 
affected by these exogenous detergents but not normally by the endogenous 
detergents, and is the chromone-containing b ile  more surfactant and 
cytotoxic than normal b ile  ? Similar effects on b ile  flow and b ilia ry  
transport maxima have recently been reported following infusion of 
endogenously detergent b ile  salts (Kitani and Kanai, 1981) in rats . 
Coleman's concept of a continuing pattern of erosion and repair
of :a chromone-induced imbalance in this natural pattern, has been alluded
to in the previous Chapter. Attempts to elucidate this phenomenon were
undertaken, based on the simple premise that normal dog b ile  might be
less detergent than dog b ile  containing FPL 52757. Surface tension
measurements and cytotoxicity were assessed using previously described
techniques (see Chapters 4 and 5). These unpublished results fa iled  to
distinguish between normal b ile  and b ile  containing the drug and are
not described in d e ta il. Suffice i t  to say that i f  this premise is not
an over-simplication, then either the methods were insensitive and the
natural detergency of the b ile  masked increased surface tension and
detergency or that i t  is not the concentration of detergent molecules
in the b ile  but th e ir concentration in the cells lin ing the hepatobiliary
trac t prior to passage into the b ile  that is crucial. Saturation of
b ilia ry  excretion and subsequent accumulation of the drug in the
hepatocytes is suggested as the probable cause of to x ic ity  (see Chapter 6).
I t  could be further postulated that the cells o f the hepatobiliary trac t
would be in the 'f ro n t- l in e 1 of this accumulation, and highest ce llu la r
drug concentrations would be found in the membrane ; ;. Further
evidence' fo r the importance of the V„ ■ for excretion into the b ile  isr max
provided by comparison of FPL 52757 and FPL 57787 (Proxicromil).
Inter-drug variations in hepatobiliary excretion and th e ir  toxicological 
im plication.
The b ilia ry  excretion in dog for FPL 52757 is approximately
1 -I nlaX
0.5 mg kg" hr" (see Chapter 6 ), This is about half that of FPL 57787 
which ranged from 0.09-1.25 mg kg"  ^ hr"^ (Smith, 1980). Of the two,
FPL 5,2757, following oral dosing, is the more potent hepatotoxin in the dog 
(unpublished data from Fisons Safety Evaluation F iles ). However,
FPL 57787 has greater surfactant properties and is more toxic in v itro  
(see Chapter 5 ). The anomaly between in v itro  and in vivo results might 
be explained by the greater hepatic accumulation of FPL 52757 resulting  
from slower b ilia ry  excretion (see Table 7 .2 ).
Table 7.2 A comparison between two hepatotoxic chromones
^max ^or b ilia ry  excretion FPL 52757 < FPL 57787
In vivo to x ic ity  in dog FPL 52757 > FPL 57787
Detergency per se. FPL 52757 < FPL 57787
In v itro  to x ic ity  FPL 52757 < FPL 57787
Alternative or contributory reasons for species variation
Interspecies variation in hepatobiliary excretion: The molecular weight threshold 
for b ilia ry  excretion has been shown to vary in ra t, rabbit and guinea-pig (Hirom 
e t a]_, 1972) apparently dependent on the excretory process i ts e l f  and not to 
differences in b ile  flow. Associated with this the Vmax for b ilia ry  excretion 
is lik e ly  to vary. This could be offered as an explanation for species 
variation in to x ic ity  amongst slow metabolizers. However, i t  certainly cannot 
be extrapolated further as metabolism and subsequent renal excretion o f polar 
metabolites o f FPL 52757 by fast metabolizers w ill reduce the significance of 
b ilia ry  excretion in these species.. The concentration of unchanged FPL 52757 
in the b ilia ry  trac t appears to be an important factor in the development of 
to x ic ity . Thus in the ra t even a fte r i .v .  bolus ( a mode of administration 
lik e ly  to exaggerate the b ilia ry  concentration)injections o f FPL 52757 b ile  
concentrations of unchanged compound were only a fraction o f those achieved in
dogs receiving infusions (e .g . Rat: i .v .  bolus 20 mg kg~^, max. concn <200pg ml ^
-1 -1 -1 of b ile ; Dog: 4 mg kg h" i .v .  infusion; max concn > 800yg ml of b i le ) .
Interspecies differences is susceptib ility  of the hepatobiliary trac t: In
publications by Coleman: .et aj_ (1980a .&Jb) the susceptib ility of erythrocytes from
d ifferen t species is related to species variation in phospholipid content, in
particu lar resistance to membrane damage is related to high sphingomyelin content.
Coleman suggests that since b ile  canalicular membranes have re la tiv e ly  high total
sphingomyelin content ; . th is may contribute to their resistance to b ile  s a lt
attack. Correspondingly species variation in sphingomyelin levels in the b ile
canalicular membrane may be related to d iffering  species susceptib ility  to
detergent drugs which are readily excreted in  the b ile .
Idosyncratic to x ic ity : In a number of accounts where idosyncratic hepatotoxicity
has been reported (Dujovne, 1977) i t  is inferred that detergency o f the drug may 
be the cause of to x ic ity  and that a better understanding of the pharmacokinetics 
of the drug might enable prediction of to x ic ity . This concept is exemplified by 
the toxicokinetic comparison of the two detergent chromones FPL 57787 (Proxicromil) 
and FPL 52757 (see above).
V a ria b ility  in human response to FPL 52757
In the introductory chapter hypersensitivity and idiosyncratic responses 
to drugs are mentioned in the section on causes of to x ic ity . I t  should 
be considered that as the mechanisms involved in drug-induced to x ic ity  are 
9enerally better understood the incidence o f adverse drug effects defined as 
idiosyncratic w ill decline. Certainly the hepatotoxicity that occurred in  
20I  o f patients with FPL 52757 may have appeared at f i r s t  sight to be 
idiosyncratic. However, as a result o f the investigations
in both man and animals in this thesis i t  .is possible to
speculate that the incidence of hepatotoxicity could have been predicted. 
The animal data shows that those species which metabolise the compound 
slowly are susceptible and fast metabolisers are not. I f  the implications 
of these species variations in metabolism are extrapolated to man one 
might expect that the 20% of patients susceptible to to x ic ity  represent 
a group of the population that are slow hydroxylators and the remaining 
80% metabolise the chromone su ffic ien tly  rapidly so as to avoid the 
adverse reactions. This is mere conjecture and i t  would equally be 
suggested that these individuals have vulnerable hepatobiliary tracts  
or a particu larly  low V for b ilia ry  excretion, or that a completely
Ilia  a
d iffe ren t mechanism operates in man. However, as numerous other examples 
exist where sub-groups ' (10-30%) in given human, populations respond
abnormally to drugs because of differences in metabolic capacity, 
defective hydroxylation of FPL 52757 in 20% of the patient population 
would seem a lik e ly  explanation for the incidence of FPL-induced hepato­
to x ic ity  seen in man.
Of the previous examples of individual variations in the human 
population with toxic consequences isoniazid acetylation is probably the 
best documented. Slow acetylators are more lik e ly  to develop peripheral 
neuritis (Devadetta et a1_, 1960), and fast metabolisers are lik e ly  to 
develop hepatotoxicity (M itch e ll, et aj_ (1975).
*
More recently, and of greater relevance to the present problem, i t  
has been observed that 91% of a British white population effect rapid 
4-hydroxylation of debrisoquine (see Figure 7.1)-
Tls .NH2
C
I
NH
4-Hydroxydeb r i soqui ne
NH.
Debrisoquine 
Figure 7.1
*(since debrisoquine is poorly metabolised by the dog (Allen et jr t , 1976)
whereas 9% were characterised by an impaired a b ility  to hydroxylate 
(Mahigoub e t al_, 1977). In this small group there was subsequent 
greater b io ava ila b ility  and a greater tendency to develop postural 
hypotension. Furthermore, these individuals, typecast for th e ir  
re la tiv e ly  poor a b ility  to metabolise debrisoquine, were re la tive ly  
poor oxidisers o f other compounds, for example, phenacetin, guanoxan 
(Sloan £ t  jf [ ,  1978) and s-carboxymethyl-L-cysteine (Waring, et al_, J981)
Those findings may have practical implication in the development 
of new drugs and the use o f drugs in the future. Discoveries of this 
nature may^open up many new possib ilities  of increasing our understanding 
of the inter-individual differences in the metabolic handling and 
resultant responses to drugs and toxic substances. I f  a population could 
be profiled prior to therapy for metabolic capacity many useful drugs 
may be retained safely. For example, i f  fast metabolisers of FPL 52757 
could be distinguished from slow metabolisers prior to medication, 80% 
of a given human population might benefit from the anti-asthmatic properties 
of this chromone without serious side-effects, and as a consequence o f this 
work i t  could be confidently predicted that lower concentrations of FPL 
52757 would be perfectly safe in man.
In a parallel yet converse situation the hepatotoxicity o f two 
detergent erythromycin derivatives might have been avoided. Dujovne 
(1978) has related the hepatotoxicity o f erythromycin estolate (ee) 
and erythromycin cetyl sulphate (ec)to th e ir  surfactant properties. Both 
ee and e (Robinson, 1962; Dujovne, 1978) have been reported to produce 
hepatotoxicity in man. The complete drugs, ee and ecconsist o f a 
combination of the erythromycin base and a detergent molecule, e ither  
lauryl sulphate or cetyl sulphate respectively. The detergents are 
added to enhance gastrointestinal absorption o f the a n tib io tics . Since ee 
is now thought to be hydrolysed by an esterase (unpublished communication), 
i t  seems probable that the resultant release o f the detergent molecules 
lauryl or cetyl sulphate and subsequent accumulation in the hepatocytes 
and hepatobiliary system could account for hepatotoxicity. I f  this is the 
case i t  would be the fastest metaboliser in  the human patient population 
that would be a t r isk . Again, i t  is possible that these individuals  
could be identified  prior to therapy by pre-screening and the drug used 
safely.
HAVE THE ORIGINAL OBJECTIVES OF THIS RESEARCH PROGRAMME BEEN MET ?
In Chapter 1 the reasons for the study of the mechanism of 
hepatotoxicity of FPL 52757 were lis ted  as follows:-
a) An understanding of the mechanism of biochemical to x ic ity  
might be helpful in the design of new and non-toxic drugs.
b) I t  seemed probable that a new type of biochemical mechanism 
of to x ic ity  might be uncovered.
c) Chemical hepatotoxicity occurred in man which was not 
previously observed in animal to x ic ity  studies, an under­
standing of this species variation is important for future 
drug safety evaluation.
To summarise, i t  is clear that these questions have been answered 
to varying degrees. Taking them in reverse order:-
Species variation in hepatotoxicity response to FPL 52757 
is d irec tly  related to metabolic capacity and the bio­
a v a ila b ility  of the parent compound. Species which metabolise 
the compound slowly are more lik e ly  to be susceptible to 
to x ic ity .
Although a novel biochemical mechanism for hepatotoxicity 
has not been uncovered, a re la tive ly  l i t t l e  known mechanism 
has been highlighted.
-  An understanding of the mechanism of to x ic ity  may help in the 
design of new and non-toxic drugs for administration by oral 
routes. For such compounds the detergency aids absorption.
Whilst retaining this property and efficacy i t  could be important 
to look fo r chromone structures, which by virtue of th e ir  physical 
structural properties are accessible to substantial and rapid 
metabolism and excretion. As further information accumulates on 
the pharmacokinetic response of man and other species to anutrients 
such predictions may become a re a lity .
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APPENDIX 2 
Table A2.1
GUINEA-PIG EXPERIMENT 
SUMMARY OF LIVER MICRO HISTOPATHOLOGY
Guinea-Pig
Treatment, Group & No.
Liver Pathology
1 N
Control ■ 2 s N
3 N (21.4)
1 ■ Isolated areas of s light necrosis. 
Vaculation in necrotic areas. 
Chronic inflammation.
Test 
100 , 
mg kg, 
day 1
2
3
As above, but only a very s light e ffect. 
N (20.0)
1 Cytoplasmic vaculation
Test 
200 , 
mgkgT 
day
2
3 Cytoplasmic vaculation
, 1 V . . ■:
Test 
300 , 
mgkgT 
day
2 ;  
: 3
Marked generalised cytoplasmic 
vaculation
N = normal
-  = no slide prepared 
() = mean liv e r  weight gm.
TABLE A2.2 PLASMA ENZYME ANALYSIS
Individual values. Mean values for each in parenthesis.
Enzymes
Group and 
Treatment
Aik. Phos.
(u/ l )
ICDH
(u/ l )
GPT
(u/ l )
Control 
(Day 19)
423 
433 
. 460
(438.8 + 6.37)
29.7
. 29.7
29.0
*
(29.3 + 0.21)
23.8 
23.7
26.9
(24.8 + 0 .6 )
Test 1 613.2 59.8 39.7
(Day 19) , , 
(200 mgkg day )
388.8 65.0 36.0
436.5 39.7
*
25.5
(479 + 55.7) (54.8 + 6 .3 ) (53.4 + 3.34)
Test 2 343 36.0 10.7
(Day 3) , , 
(200 mgkg day )
561.9 31.2 7.11
(452,45) (33.6) (8.92)
Test 3
(Day 3) , 
(300 mgkg day )
396.8) - 10.7)
-k
Treatment group sign ifican tly  d iffers  from the control at a probability  
of less than 0.1.
Standard Error +
Plasma samples were collected 4-5 hours a fte r the fin a l treatment fo r  
the control and test groups. Samples collected from groups 2 and 3 were 
taken following the onset of acute toxic symptoms.
TABLE A2.3 MEAN LEVELS OF FPL 52757 PER GROUP IN FAECES 
URINE, BILE AND PLASMA
Compound
Urine Faeces Bile Plasma
Group and 
Treatment
Control
Test 1 _•] 245yg/ml 866yg/gm 161.5yg/ml 125yg/ml
(lOO-.mgkg"
oay 1)
day"1)
Test 3 NS NS NS NS
(200 .mg kg”1 
day ‘ )
NS - No sample
*A trace of another metabolite was found in the b ile  samples of tes t group 2.
Urine and faeces samples were collected for 24 hrs a fte r a dose of FPL 52757. 
Plasma and b ile  samples were collected from test group 1^4-5 hours a fte r  
the fina l dose. Samples from test group 2 were taken following death or 
onset of symptoms of acute to x ic ity .
Test 2 
(200 mgkg'
NS NS 765yg/ml* 36Cyg/mT
FERRET EXPERIMENT
Table A2.4 LIVER WEIGHT AND PATHOLOGY
Ferret and 
Treatment
Liver Weight 
gm
Liver Pathology
1. Control 47.5 Normal
2. 200 mgkg"1 day"’ 1 42 Normal
3. 300 mgkg"1 day 1 45 Normal
Table A2.5 PLASMA ENZYME LEVELS - results illu s tra ted (U/L)
Enzymes ICDH
ru/L)
GPT 
_ (U/L)
Aik. Phos. 
(U/L)
Day No. 0 3 4 5 0 3 4 5 0 3 4 5
Ferret and 
treatment
1 (Control) 17 12 > 14* 50 26 40 51.0 30 - 22*
2(200mgkg"1 
day ) 10 20 10 16.5 56 
(8)
9.5 - 27*
(12)
52 33 22 11*
3(400mgkg”1 
day ) 18 20 - 40 14.5 - - 52 30
* Values from terminal aorta bleed 
() Values from ta i l  bleed 
-  no values obtained.
TABLE A2.6 LEVELS OF FPL 52757 IN PLASMA, URINE AND FAECES
Sample
Ferret, treatment 
and day of sample
Urine Plasma Faeces Bile
1. Control ; - ■ ~ .
2. Day 4 (200mgkgr1ciayr I 1)' 95 yg/ml* . • ' -  '■■•■ ■
Day 5 (200mgkg-lday~ 1) 270 yg/ml* 95 yg/ml 1700 yg/gm 1360yg/ml
3. Day 4 (400mgkgr^day’^ ) 400 yg/ml* NS NS NS
NS = No sample
*  2 other metabolites present in these urine samples which were unidentified , 
one was probably FPL 57704. Trace amounts of this metabolite were also 
found in b ile  and faeces.
(Urine and faeces samples were collected 24 hours a fte r the previous dose. 
Plasma and b ile  samples were collected approximately 3 hours a fte r  the las t 
half daily dose of FPL 52757).
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NEO-NATAL RAT EXPERIMENT
TABLE A2.9 LIVER HISTOLOGY. MICROSCOPIC EXAMINATION OF
LIVER SECTIONS FOLLOWING STAINING WITH H AND E.
Animals and 
treatment group Description of Livers
Control No. Prominent occasional chronic inflammatory
1 - 10 cell in f ilt ra t io n  in parenchyma and portal
tracts .
lOOmgkg^day”1,
Test No.
4 - 1 0 As above, however inflammatory foci in the
pyrenchyma were less numerous.
3 Prominent occasional chronic inflammatory ce ll
in f ilt ra t io n  in parenchyma and portal trac ts . 
Frequency of foci sim ilar to control. Mid- 
zonal vacuolation throughout most lobes. A 
small focus of acute inflammation beneath the 
capsule of one lobe.
1-2 Inflammatory cell in f ilt ra t io n  as in controls
with congested blood within the lobes.
-131-
TABLE A2.10 MEAN PLASMA ENZYME LEVELS (UL)
Treatment Enzyme 
Group
Alkaline
Phosphatase
(U/l)
ICDH
(U/L)
OPT
(U/L)
1. Control 441.5 (2) 
[437-448]
16.2 (5) 
[8-20]
10.9 (3)
P -18]
2. 100 mgkg^day-^ 439.1 (3) 
[431-450]
14.4 (5) 
[12-17]
20.3 (3) 
[18-24]
() = number of animals 
|J = range of values
RAT DATA
Experiment to demonstrate the effect of defic ient d iet and phenobarbitone 
treatment.
TABLE A 2.ll HISTOLOGY REPORT ON RAT LIVERS
Group Rat Comments
1
Experimental d iet 
control A ll livers normal
Normal d ie t plus 
-1 -1 200 mgkg day .
ii ii
Experimental d iet + 
200 mgkg"1 day"1.
9
10
11
12
13
14
15
16
17
18
19
20 
21 
22
23
24
Most livers appeared normal. 
Livers from rats 20 and 23 had 
pale stained hepatocytes in 
centrilobular areas with some 
vacuo!ation. No signs of necrosis
25
& 26 Most livers appeared normal.
27 Livers from rats 26 and 31 had
Experimental d ie t 28 paled stained hepatocytes in
with phenobarbitone 29 centrilobular areas with some
in the drinking water 30 vacuolation. No signs of necrosis.
+ 200 mgkg day . 31
32
5 34 One liv e r  was normal. 5 livers  had
pale stained hepatocytes in cen tri- 
Experimental d iet with 36 lobular areas with some vacuolation.
phenobarbitone in the 37 No signs of necrosis,
drinking water + 38
400 mgkg" day" . 39
TABLE A2.12. PLASMA.ENZYMES
a) Average G.L.D.H. Levels (IU). .in Rats per Group
Group No. Prior to 
Treatment Day 0 Day 6 Day 14/15
1 5 (4-6) 6.25 (4-11) 4.3 (0.13) 3.5 (3-4)
Experimental d iet 
Control
M [4j M [4]
2 ; 5 (4-6) 6.0 (5-7) 3.8 (3-5) 5.5 (5-6)
Normal d iet , 
200 mgkg day
[4] M M
3 5.4(3 .7) 9.4 (1-25) 4.6 (3-10) 7.0 (1-20)
Experimental d ie t, 
+ 200 mgkg" day
[14] 0 *1 P4J [ " ]
4 5 (4-6) 9.3 (4-21) 5.5 (3-8) 7.0 (2-15)
Experimental d iet 
with phenobarbitone 
in the drinking water 
+ 200 mgkg" day"
[s] [8] [8] [8]
5
Experimental d iet 
with phenobarbitone 
in the drinking water 
+ 400 mgkg" day"
5.5 (4-6) 
[8]
5.3 (0-12) 
[8]
5 (4-6) 
[8]
11
[8]
() range of values
[J number of animals in each group
TABLE A2.13 PLASMA ENZYMES
b) Average G.P.T. Levels (IU) in Rats
Group No. Prior to 
Treatment
Day 0 Day 6 Day 14/15
1
Experimental d iet 
control
8 0 .3 (66 -91 )
M
54.5 (47-61) 
[4]
68.8(51-75)
r a
64 (57-69)
W
2
Normal d ie t ' , ' 
200 mgkg” day”
70.5 (66-78)
p j
62.3 (57-70)
P I
52 (38-67)
P ]
54.3 (48-60)
PJ
3
Experimental d ie t, 
+ 200 mgkg"1 day"
63.6 (40-75)
P 5]
51.6 (37-73) 
[15]
68.6(48-105) 68.5 (48-98)
P * ]  . P 2,
4
Experimental d iet 
with phenobarbitone 
in the drinking water 
+ 200 mgkg day"
57.9 (49-69)
T8]
72,6 (60-83) 
[8]
97.1 (58-125) 63.1 (40-91 
[8] [8
5
Experimental d ie t 
with phenobarbitone 
in the drinking water 
+400 mgkg” day”
60.1 (48-74) 
[8]
57.6 (29-92)
r a
96.6(49-153)
P ]
101
P I
() range of values
[] No. of animals in each group
TABLE A2.14 LEVEL OF FPL 52757 AND METABOLITES 
IN yg/ml PLASMA and pg/mg LIVER
Group Number Rat
Number Plasma Liver
FPL 52757 FPL 57704 FPL 52757 FPL 57704
1
Experimental diet 1 0 0 0 0
Control 2 0 0 0 0
3 0 0 0 0 -
4 0 0 0 0
2 5 15 0 - —
Normal d iet 
200 mgkg" day
6
7
127
25
20
0
36
0
10
0
8 6 0 (6 1 *) 0 10 0
9 9* . ’
10 145 25 42 0
11 no trace 18 0
12 150 trace 72 36
3 13 165 trace 28 0
Experimental d iet + 
200 mgkg" day"
14
15
*—
32 10
16 145 trace 60 6
17 195 25 58 16
18 - . -r t
19 215 25 84 16
20 — - — ■
21 235 25 76 12
22 — — \
23 165 * 20 55 8
24 180 (171.0) 60 70 8
Experimental d iet with 
phenobarbitone in the 
drinking water ‘plus 
200 mgkg" day" .
25 60 trace 10 0
26 35 0 16 0
27 90 trace 28 4
28 —f ■ i 70 8
29 40 0 8 0
30 15 15 20 0
31 240 25 0 0
32 55(76.4) 0 0 0
33 120 500 0 0
5 34 4. . - f
Experimental d iet with 35 - -  ■ — -rr-
phenobarbitone in the 36 . 40
drinking water plus 37 -  \ — 80 80
400 mgkg" day" . 38 \ - 7
39 ; - r - r
40 . *T* —
The presence of FPL 58280 was not c learly  demonstrated, 
appeared to be present in plasma samples.
mean per group. — no sample obtained.
However, some
C .A p C f '  | l l | C | | u  l*u  u o i ; u | p  u)  q u c  c |  | cv»i» v»| jji i<_i ( v ' - ' i f t  MMM o  i i j c i d i j r  i ^ n u i u n v i u  u | i u
pretreatment and deficient d ie t.
TABLE A2.15. HISTOLOGY REPORT AND LIVER WEIGHT gm ,
Group Ferret
Number
Appearance of Liver Weight 
in gm.
1
1 Occasional foci of chronic 
inflammatory cells in the liv e r ,  
parenchyma and portal tracts.
41.3
Control 2 Minimal amount of chronic 
inflammatory cell in f iltra t io n  
mainly in the portal tra c t.
35.0
2
Phenobarbitone
Control
3
10
Usual amount of chronic 
inflammatory cell in f iltra t io n  
mainly in portal areas.
44.7
34.2
3 - i  FPL 52757 lOOmgkg 1
.-I
day plus
4
5
6
Usual amount of chronic 
inflammatory cell in f iltra t io n  
mainly in portal areas.
31.6
43.9
38.0
phenobarbitone
7 Occasional prominent foci of chronic 
in f ilt ra t io n  in the liv e r , parenchyma 
and portal areas.
75.6
4
FPL 52757, ■ , 
100 mgkg" day’  
+ 3-methyl- 
cholanthrene.
In one lobe a large area of b ile  duct 
pro liferation  or possibly a primary 
tumour was found. Enlarged foamy 
hepatocytes surrounded this odd area.
Mineralisation had occurred in a few 
isolated cells near to the odd area. 
Appeared to be metastatic ca lc ifica tio n  
and some necrotic ce lls .
8 Minimal amount of chronic inflammatory 45.6 
cell in f ilt ra t io n  in portal areas.
Vacuolation around portal areas.
9 Minimal chronic inflammatory ce ll 48.8 
in f ilt ra t io n  in l iv e r , parenchyma and 
portal areas, with marked centrilobular 
pre-necrosis a c tiv ity
5
3-methyl-
11 Minimal chronic inflammatory ce ll 
in f ilt ra t io n  in multiple small foci 
in the parenchyma and in portal tracts
42.4
•
cholanthrene
Control 12 Occasional multi-nucleated giant ce lls  44.4 were noted.
TABLE A2.16 PLASMA ICDH LEVELS (U/1)
Day -14 1 8 12 14 22 28
Group Ferret
No.
(24) (5) (3) (3-4) (2)
1
1 - 19.0 13.0 11.0 - 13.9 17.6
2 27.9 19.0 12.0 13.7 17.4 16.3
2
3 - 27.0 - - 14.9 20.9 15.0
10 ■* — 25.0 ** 25.9 20.0
4 28.9 - 16.0 8.0 8.0 25.9 37.6
3 5 35.5 - - 10.0 - 18.9 34.5
6 31.9 - 14.0 14.9 10.0 25.9 21.9
7 24.9 - 34 30.0 39.8 50.0
4 8 - - 9 - 15.0 23.9 15.2
9 33.9 20.0 12.0 22.0 25.0 41.8 132.0
5
11 28.0 16.0 13.0 - . 10.0 27.4 23.4
12 19.9 14.0 10.4 21.9 21.4
() hours a fte r las t dose o f chromone or vehicle. 
Treatment per group as for Table A2.15.
-138-
TABLE A2.17 PLASMA GPT LEVELS (U /l)
Day -14 1 8 12 14 22 28
Group Ferret
No.
(24) (5) (3) (5-4) (2)
1
1 - - - 38.7 - 58.0
2 - 62.5 38.4 38.7 28.6 32 28.6
2
3 - 65.5 ■ - - - 86.3 34.5
10 - - 40 - - 142 89.2
4 59.5 _ 16.6 41.7 169 33
3 -
5 - 29.8 - 32.7 59
6 65.5 - •18.6 71.4 16.6 32.7 23.2
7 - 123 107.1 74.0 109 -
4 8 - -  . 43 - 47.6 32.5 21.7
9 71.4 16.6 56 30.9 60.0 217.5
11 74.3 60.0 30.9 59.7 80.3
5 ■■
12 40.0 36.0 54.5 97
() hours a fte r las t dose.
Treatment per group as for Table A2.15
-139-
TABLE A2.18 PLASMA ALKALINE PHOSPHATASE LEVELS (U /l)
Day -14 1 8 12 14 22 28
Group . •• (24) (5) (3) (3-4) (2)
1 ■ _ 38.2 26 22.0 59.0
1
2 33.0 33.0 27 16,4 65.5 18.0 39.6
3 36.0 . . .  . ' 49.1 19.1 60.8
2
10 33.0 38.2 21.8 43.7 16.4 54.6
4 76,0 76,4 11,0 21,8 13.1 32.8 57.0
3 5 87.0 - 27.3 49.1 30.0 55.8
6 52,0 - 18.0 . 32.8 27.3 55.6
7 50 - 103,7 70,4 109.2 240.2 -
4 8 - 44 - - 43.7 87.4
9 98.0 - 50.1 - 76.4 54.6 90.0
11 52.4 54.6 11.0 21.8 88.6
5
12 54.6 65.5 33.0 49.1 27.3 87.9
Q  hours a fte r las t dose
Treatment per group as fo r Table A2.15.
-140-
TABLE A2.19. ANALYSIS OF SERUM SAMPLES
Group Ferret No. FPL 52757 
iig/ml
(8 hours^after las t dose) 30
5 250
3 .
6 280
8 300
4
9 190
7 170
(week 2 sample)
Trace amounts of FPL 57704 were also found in a ll samples. 
Samples taken 1.5 hrs a fte r fin a l dose
TABLE A2.20 ANALYSIS OF URINE SAMPLES*
(A) FPL 52757 Levels in Urine -ug/ml
Group Ferret No. Wkl Wk2 Wk3 Wk4
4 340 330 -
3 5 272 195 260 215
6 354 160 220 250
7 300 230 280 217
4 8 330 300 340 70
9 375 - 195 290
(B) FPL 57704 Levels in Urine -ug/ml
Group Ferret No. Wkl Wk2 Wk3 Wk4
4 150 180
3 5 155 155 170 100
6 120 45 70 220
7 55 45 70 -
4 8 75 50 420 10
9 90 - 200 200
*NB One additional unidentified metabolite was found in a ll the urine 
samples close to the origin.
TABLE A2.21 ANALYSIS OF FAECES SAMPLES*
FPL 52757 Levels in Faeces - yg/gm
Group Ferret No. Wkl Wk2 Wk3 Wk4
4 400 600 500 1100
3 5 640 1000 900 2400
6 2600 700 500 2100
7 •1640 1100 700 NF
4 8 1100 1000 800 NF
9 2600 2200 2600 NF
NF = No Faeces
Urine and faeces collected for 24-hour period following dosing.
TABLE A2.22 (A) ANALYSIS OF LIVER -  yg/gm
Group Ferret Compound 52757 Compound 57704
Number (yg/gm) (yg/gm)
; 4 .60 ■ ■ 9
4 57 9
5 42 9
3 5 51 6
6 60 12
6 60 9
7 54 -
7 54
4 8 66 6
8 66 6
9 36 6
9 50 12
TABLE A2.22 (B) ANALYSIS OF BILE* - yg/ml
Group Ferret
Number
Compound 52757 
(yg/ml)
Compound 57704 
(yg/ml)
3 5 750 360
6 • 720 315
7 570 90
4 8 630 130
9 630 620
*NB Two unidentified peaks. F irs t peak corresponded to one found in urine. 
Second not previously analysed (found a t higher levels in 5 and 5, almost 
negligible in 7, 8 and 9).
Samples taken 2 hours a fte r fin a l dose.
Experiment to demonstrate the effect of phenobarbitone and methionine on
FPL 52757 to x ic ity  in dogs.
HISTOLOGY REPORT
*
Positive Control: Centrilobular necrosis in "seastar" pattern around central vein.
Normal hepatocytes around portal areas. Bile duct enlargement and 
pro life ra tio n , with signs of erosion of b ile  duct walls.
Phenobarbitone pretreated dog: Isolated necrotic hepatocytes, mainly
in centrilobular region of many lobes.
Positive Control dog: Liver congested with blood. Marked areas of "seastar" 
bridging necrosis. Nuclear fragmentation-
Fatty change occurred with increased deposits in a "seastar" centrilobular 
pattern. Normal hepatocytes were found around portal areas.
Bile ducts. Numerous b ile  ducts showed extreme d ila tio n ,
swollen with m aterial. P ro liferation of b ile  ducts around the swollen 
ducts.
Methionine pretreated dog: Slight centrilobular necrosis. Some b ile  duct
enlargement with erosion of b ile  duct walls.
*(see Rappaport, 1976)
TABLE A2.22 PLASMA ENZYME LEVELS IN DOGS
Day of Study 
Pretreatment
Animal
No.
ALP
IU
GOT.
IU
GPT
IU
GLDH
IU
C1ii 192 22 30 11 222 33 37 2
2 ii 241 33 34 1
3 » '329 32 31 3
4 it 275 29 33 1
5 a 278 25 34 6
8 ii 329 29 31 2
9 ii 367 27 33 0
n ii 304 23 28 1
12 ii 284 25 40 6
15 ii 317 30 49 6
16 ii 297 46 83 24
17 ii 295 29 63 13
18 H 289 23 56 1
19 it 319 29 49 3
22 ii 323 25 36 3
23 •• 311 22 35 1
26 ii 289 49 162 41
30 ii 262 26 113 7
Cl = Control Dog 
TABLE A2.23
Day of Study 
Pretreatment
Animal
No.
ALP
IU
GOT
IU
GPT
IU
GLDH
IU
P 154 41 35 1
1 P 155 50 44 2
2 P 165 51 45 1
3 P 168 43 38 1
4 P 162 48 40 1
5 P 182 44 43 3
8 P 150 55 38 3
9 P 175 55 59 8
11 P 224 85 257, 53
12 P 231 119 309 53
13 P 251 144 425 52
P = Phenobarbitone pretreatment
TABLE A2.24 PLASMA ENZYME.LEVELS IN DOGS(CONTINUED)
Day of Study Animal ALP
IU
GOT
IU
GPT
IU
GLDH
IU
M 129 35 44 1
1. «i 190 70 74 1
2 ii 177 31 63 2
3 ii 179 25 51 2
5 ii 155 31 41 3
6 ii 180 37 30 1
8 ii 164 31 36 4
9 ii 143 27 32 2
10 it 152 26 30 7
n ii 135 31 32 5
12 H 134 31 29 1
15 ii 138 36 37 5
18 ii 143 42 92 15
20 ii 145 43 110 12
23 ii 140 52 114 12
24 ii 129 29 95 5
25 ii 126 29 80 3
26 ii 126 29 78 5
29 ii 122 34 52 4
30 u 116 32 47 4
32 n 113 36 42 4
36 ii 114 24 34 3
38 ii no 28 38 5
40 ii 126 32 39 8
43 ii 115 26 34 2
44 a 128 32 35 3
46 ii 121 26 30 2
47 ii 119 36 31 1
50 ii 130 34 30 1
51 ii 122 29 30 1
52 ii QNS QNS 34 8
53 it QNS QNS 60 26
54 ii 141 42 61 14
57 ii 138 64 58 19
58 ii 148 39 85 27
59 ii 162 41 113 39
60 n 153 46 123 15
61 ii 148 37 107 13
64 ii 145 33 71 3
65 H 152 32 58 3
67 u 151 31 51 2
68 ii 181 91 211 151
69 ii 261 149 672 187
M = methionine pretreated
TABLE A2.25 PLASMA ENZYME LEVELS IN DOGS (CONTINUED)
Day of Study Animal ALP
IU
GOT
IU
GPT
IU
GLDH
IU
V 192 33 33 1
1 II 224 35 38 1
2 II 215 32 34 5
3 II 225 26 35 2
5 II 204 54 99 54
6 II 223 80 162 95
8 II 208 25 89 16
9
it 201 21 65 3
10 ii 208 24 58 3
11 »• 208 73 157 98
12 ii 263 141 410 143
15 ii 2550 4700 9140 175
= Control dog 2.
TABLE A2.26 LEVELS OF FPL 52757 AMD FPL 57704 IN PLASMA,LIVER AND BILE
DOG Compound
Material
FPL 52757 FPL 57704
Cl Plasma 190 yg/ml Trace
Liver -  Lobe 1 58 yg/gm -
- Lobe 2 60 yg/gm —
Bile 8,8000 yg/ml -
P Plasma - 2hr 192.5yg/ml -
- 9hr 125.5yg/ml -
Liver - Lobe 1 32 yg/ml
- Lobe 2 44 yg/ml —
- Lobe 3 68 yg/ml -
Bile 5,000 yg/ml -
C2 Bile 8,000 yg/ml Trace
Faeces 900 yg/gm -
Urine 205 yg/ml -
M Plasma 180
(100-260 yg/ml)
Trace
Liver - Lobe 1 60 yg/gm
- Lobe 2 50 yg/gm -
Bile 7,000 yg/ml -  ”
Faeces 900 yg/gm -
Urine 175 yg/ml 45 yg/ml
CT =■ Control; P = Phenobarbitone pretreated .02= Control; M = Methionine pretreated. 
Urine and faeces samples collected over a twenty-four hour period.
Plasma samples taken 2 hours a fte r dosing.
The presence or absence of an additional metabolite FPL 58280 in the faeces 
was not c learly demonstrated.
SPECIAL RODENT DIET defic ient in selenium, Vitamin E and methionine 
contained these components at the following levels:-
Selenium > 0.005 mg kg**l
-1Vitamin E 2.5 mg kg
Methionine 0.21% of to ta l d iet
1.5% of to ta l protein.
In addition cysteine was deficient ( i .e .  0.15% of to ta l d ie t or
1.1% of to ta l protein). The minimum protein requirement fo r rodents
is 4.5% of to tal d ie t. The special d iet had a total protein content
of 2.6%.
The d iet was supplied by B.P, Nutrition (U .K .), S tepfield, Witham, 
Essex, CM8 3AB.
APPENDIX 3 (Appendix to Chapter 6)
DOG RESULTS
TABLE A3.1. CLINICAL CHEMISTRY AND DRUG CONCENTRATIONS FROM PLASMA SAMPLES 
FOLLOWING INTRAVENOUS INFUSION OF FPL 52758 at 36 mg kg"1 hr"1
Time ALP GOT GPT GLDH FLP 52758 
vg ml”1
0 218 44 82 1 —
I  hr 224 (1.02) 49 (1 .1) 87 (1 .1) 5 (5 ) 330
1 hr 231 (1.05) 53 (1.2) 89 (1 .1) 5 (5) 425
11 hrs 242 (1.11) 57 (1.3) 108 (1 .3) 7 (7 ) 480
2 hrs 253 (1.16) .64 (1.5) 100 (1 .2) 7 (7) 53o
2\ hrs 265 (1.21) 73 (1 .7) 98 (1 .2) 8 (8) 345
3 hrs 300 (1.4) 90 (2 .1) 109 (1 .3) 9 (9 ) 220
3| hrs 342 (1.6) 100 (2 .3) 116 (1 .4) 9 (9 ) 240
() Increase 
*  FPL 52758
expressed as x 
is the soluble
normal level, 
sodium s a lt o f FPL 52757.
TABLE A3.2. CLINICAL CHEMISTRY AND DRUG CONCENTRATIONS FROM PLASMA SAMPLES
FOLLOWING INTRAVENOUS INFUSION OF FPL 52758 at 12 mg kg-1 hr-1
Time GLDH ALP GOT GPT FPL 52758 
vg mg”1
0 3 150 52 57 - ■
§ hr 2 (0 .7) 146 (1 .0) 53 1.0) 55 1.0) 135
1 hr 2 (0.7) 160 (1.1) 57 1.1) 58 1.0) 250
1| hrs 3 (1 .0) 181 (1 .2) 54 1.0) 60 1.6) 235
2 hrs 4 (1.3) 162 (1.1) 52 1.0) 53 1.0) 360
2| hrs 3 (1 .0) 187 1.3) 51 1.0) 56 1.0) 285
3 hrs 5 (1.7) 208 (1.4) 52 1.0) 56 1.0) 330
3| hrs 5 (1.7) 236 (1 .6) 57 1.1) 61 1.1) 225
4 hrs 5 (1.7) 266 (1.8) 59 1.2) 56 1.0) 250
4§ hrs 5 (1 .7) 291 (1.9) 64 1.2) 51 0.9) 250
() Increase expressed as x normal' le v e l.
TABLE A3.3. CLINICAL PATHOLOGY AND DRUG CONCENTRATIONS FROM PLASMA SAMPLES
FOLLOWING INTRAVENOUS INFUSION OF FPL 52758 at 4 mg k g '1 hr~1
Time ALP GOT GPT GLDH FPL 52758 
yg ml’
o 184 123 186 5 _
i  hr 197 (1.1) 116 < 1 198 (1 .1) 6 (1 .2) 70
1 hr 1 9 0 (1 .0 ) 110 < 1 193 (1 .0) 4 (0 .8) 140
1| hrs 198 (1 .1) 104 < 1 197 (1 .1) 6 (1 .0 ) 140
2 hrs 2 0 4 (1 .1 ) 96 < 1 193 (1 .0) 8 ( 1 .6 ) 160
21 hrs 224 (1 .2) 94 < 1 196 (1.1) 11 (2 .2) 205
3 hrs 248 (1 .3) 93 < 1 198 (1 .1) 13 (2 .6) 190
31 hrs 275 (1 .5) 94 < 1 198 (1 .1) 14 (2 .8) 180
4 hrs 308 (1 .7) 100 < 1 205 (1 .1) 15 (3) 160
41 hrs 337 (1 .8) 97 < 1 202 (1 .1) 15 (3) 160
() Increase expressed as x normal level
RAT RESULTS
Bile Flow
TABLE A3.4 (a ) : RAT 1 TABLE A3.4 (b ): RAT 1
+ SKF 525A 50mg kg"1
Prior to 27.2 Prior to 25.0
Dosing Dosing 21.4
19.4
1.45 28.6 2.15 22.2
3.40 26.1 4.30 22.2
5.45 24.0 6.45 22.2
7.45 24.0 9.00 22.2
9.30 28.6 11.15 22.2
11.45 22.2 13.28 22.5
13.50 24.0 15.45 21.9
16.00 23.0 18.15 — 20.0
18.00 25.0 20.45 20.0
20.10 23.1 24.00 15.4
22.30 21.4 27.00 16.6
30 21.3
45 23.3
60 21.1
90 19.1
TABLE A3.4 (c) RAT 3 . TABLE A3.4 (d) RAT 4
FPL 52758 20 mg kg-1 FPL 52758 30mg kg'
+ SKF 525A. + SKF 525A_.
Timein Min Flow ra t yl rain Time in Min. Flow Rate jiT rain 1
Prior to 21.4 Prior to 27.3
Dosing Dosing 23.1
24.0
2.50 17-6. 1.48 27.8
5.45 12.8 3.46 24.2
9.15 18.18 5.50 . 23.0
11.40 11.8 8.00 24.0
15.55 14.8 10.05 24.0
19.30 22.2 12.10 23.1
21.45 15.3 15.20 23.1
23.20 21.4 17.30 24.0
25.40 21.4 19.40 24.0
28.00 20.7 21.45 24.0
30.25 21.4 23.50 24.0
32.25 21.4 25.55 24.0
35.05 21.4 27.00 24.0
37.40 19.4 29.00 24.0
40.20 20.7 31.30 20.0 "
42.45 17.6 34.35 16.2
48.50 17.6 37.45 15.8
51.40 16.6 40.30 17.6
34.40 17.6 45.00 11.1
37.30 ' ; 17.6
60.30 16.6
75.5 v 15.0 ■'
90.5 ; 16.6
105 16.0
TABLE A3.4 (e) RAT 5
FPL 52758 50 mg kg"1 
+ SKF S25A 50 mg kg
TABLE A3.4 ( f )  RAT 6
No treatment
Time in Min Flow Rat pi min Time in Min. Flow Rate pi min"1
Prior to 18.2
Treatment 18.2
2.25 20.7 1.50 27.3
4.45 20.7 3.45 26.1
7.15 21.4 5.40 26.1
9.40 20.7 7.35 26.1
12.00 21.4 9.30 26.1
14.20 21.4 11.25 26.1
16.40 21.4 13.20 26.1
19.00 21.4 15.20 25.0
21.20 21.4 17.20 25.0
23.30 23.1 19.20 25.0
25.40 23.1 21.20 25.0
28.00 21.4 23.20 25.0
30.00 25.0 23.20 25.0
32.05 24.0 25.20 25.0
34.05 25.0 27.20 25.0
36.10 24.0 29.25 25.0
38.15 24.0 31.35 25.0
40.10 25.0 34.40 25.0
42.10 25.0 50.20 24.0
44.10 27.3 65.10 23.1
45.50 27.3 80.20 24.0
47.40 28.5
51.20 26.5
TABLE A3.5 (a) FPL 52757 AND FPL .57704 CONCENTRATIONS IN THE
BILE FOLLOWING I.V . BOLUS OF 20 mg kg"1 FPL 52758 (Rat 1)
Time in 
Mins
FPL 52757 Concentration in 
p9 ml"
FPL 57704 
ng ml
5.45 100 126
16.0 126 144
30 88 158
45 106 207
60 88 185
90 74 118
100 82 40
TABLE A3.5 (b) FPL 52757 AND FPL 57704 CONCENTRATIONS IN THE
BILE FOLLOWING I.V . BOLUS OF 20 mg kg" 1 FPL 52758 AND
PP*ETREATMENT WITH SKF 525A 50 mg kg-1 .
Time in 
Mins
FPL 52757. 
Concentration in ng ,-1  FPL 57704 m 1 >
vg ml"
10 164 10
23 164 102
35 no 56
50 100 72
60 100 80
75 120 74
90 66 -
105 69 45
125 78 28
TABLE A3.5 (c) FPL 52757 AND FPL 57704 CONCENTRATIONS IN THE M
BILE FOLLOWING I .V.  BOLUS INJECTION'OF 50 mg k g '1 FPL 52758
AND PRETREATMENT WITH SKF 525A.
Time in 
Mins
FPL 5275' Concentration in 
yg ml”
FPL 57,7^4 
yg ml"
7 500 68
20 400 108
25 196 76
35 268 220
47 200 200
57 316 220
70 190 148
TABLE A3.5 (d) FPL 52757 AND FPL 57704 CONCENTRATIONS IN THE i, 
PLASMA FOLLOWING AN I.V . BOLUS INJECTION OF 20 mg kg 
FPL 52758
Time in 
Mins
FPL 52757 Concentration 
yg ml"
in FPL 57704 
yg ml"1
2 197 1
6 119 v  - ' 1
11.0 79 -
15,0 115 45
22.0 70 70
40.0 42 42
45.0 47 47
60.0 37 37
90,0 15 17
TABLE A3.5 (el FPL 52758 CONCENTRATIONS IN THE PLASMA* FOLLOWING I.V .
BOLUS INJECTION OF 20 ma kg"1 FPL 52758 + PRETREATMENT 
WITH SKF 525A 50 mg kg T i.p . ____________
Time in Mins FPL 52757 Concentration 
in yg ml
2. ; 100
: ..4 . . 88
. 6 90
8 80
11 38
15 55
20 88
30 26
60 14
90 20
120 15
*No -OH metabolite present
TABLE A3.5 ( f )  FPL 52757 AND FPL 57704 CONCENTRATIONS IN THE .
PLASMA FOLLOWING AN I.V . BOLUS INJECTION OF 50 mg kg’ 1 FPL 
52758 + PRETREATMENT WITH SKF 525A 50 mg kg"1 i.p .
Time in 
Mins
FPL 52757 Concentration in 
yg ml"
FPL 57704 
yg ml
2 300 trace
4 312 trace
8 240 21
11 250 trace
22 250 28
30 146 18.6
45 220 0
60 146 o
90 85.3 0
TABLE A3.6 (a) ALKALINE PHOSPHATASE (ALP) CONCENTRATIONS IN THE , 
BILE FOLLOWING AN I.V . BOLUS INJECTION OF 20 mg k g '1 
OF FPL 52758
Time (in  mins) ALP ( I .U .)
10 45
30 55
45 65
60 60
90 72
TABLE A3,6 (b) ALP CONCENTRATIONS IN THE 
INJECTION OF 20 mg.kg"1 OF 
SKF 525A 50 mg kg"1 i .p .
BILE FOLLOWING AN I.V . BOLUS 
FPL 52758 + PRETREATMENT WITH
Time (in  mins) ALP ( I .U .)
15 80
46 80
60 85
75 75
90 80
125 75
TABLE A3.6 (c) ALP CONCENTRATIONS IN THE BILE FOLLOWING AN I.V . BOLUS
INJECTION OF 50 mg.kg’*1 OF FPL 52758 + PRETREATMENT WITH 
SKF 525A 50 mg kg i.p ._____________________________ __
Time (in  mins) ALP ( I .U .)
10 55
22 65
30 50
42 40
50 70
65 90
77 75
TABLE A3.6 (d) ALP CONCENTRATION IN THE PLASMA FOLLOWING AN I.V . BOLUS 
INJECTION OF 50 mg kg’ 1 FPL 52758 AND SKF 525A 50 mg kg 
I.P .
Time(in mins)
0
11
45
ALP ( I .U .)
394
334
420
Meeting on ’’Extrapolation from Animals to Man”
TITLE Toxicity studies on EPL 52757 an oral anti-allergy compound.
ABSTRACT EPL 52757 (6, 8 -diethyl-5-hydroxy- 4 -oxo-4H-l- benzopyran - 2 -
carboxylic acid) was devloped as an orally effective anti-allergic drug 
Treatment of-human volunteers for 2 weeks at 5mg kg"~* day~* did not reveal 
any evidence of toxicity. However, the drug was found to cause an 
incidence of abnoimal liver function in man after treatment for one month 
at daily doses of approximately 5 mg kg""*. The effects were generally minor 
and were readily reversible when treatment stopped. Nevertheless they were 
sufficient to halt the development of the compound for chronic use at 
this dose level. Previous extensive animal studies in five species, rat, 
hamster, rabbit, squirrel monkey and cynomolgus monkey, of up to six months 
duration, had failed to indicate any hepatotoxicity due to the drug. Subsequent 
further animal studies in rat, mouse, rabbit, ferret, guinea-pig, baboon 
and dog confirmed that most species are not readily susceptable to a 
hepatutoxic effect of EPL 52757, with the exception cf the dog. Deatn 
primarily due to liver failure could be induced in dogs by repeated doses 
of 20 mg kg~* day""*. The cause of the species variation in response to 
this compound has been investigated and it is apparent that metabolic 
and pharmacokinetic differences affect toxicity. The dog is a species 
which is incapable of clearing the compound rapidly by metabolism and as 
a consequence is susceptible to its hepatotoxic effects. The parent 
compound appears to be responsible for the hepatotoxicity and the susceptibility 
of a species is probably related to its ability to clear the compound.
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